<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29221491</article-id><article-id pub-id-type="pmc">5723032</article-id><article-id pub-id-type="publisher-id">318</article-id><article-id pub-id-type="doi">10.1186/s13195-017-0318-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ostrowitzki</surname><given-names>Susanne</given-names></name><address><email>ostrowitzki.susanne@gene.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lasser</surname><given-names>Robert A.</given-names></name><address><email>robert.lasser@medday-pharma.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dorflinger</surname><given-names>Ernest</given-names></name><address><email>edorflinger@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Scheltens</surname><given-names>Philip</given-names></name><address><email>p.scheltens@vumc.nl</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Barkhof</surname><given-names>Frederik</given-names></name><address><email>f.barkhof@vumc.nl</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Nikolcheva</surname><given-names>Tania</given-names></name><address><email>tania.nikolcheva@roche.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ashford</surname><given-names>Elizabeth</given-names></name><address><email>elizabeth.ashford@roche.com</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Retout</surname><given-names>Sylvie</given-names></name><address><email>sylvie.retout@roche.com</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Hofmann</surname><given-names>Carsten</given-names></name><address><email>carsten.hofmann@roche.com</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Delmar</surname><given-names>Paul</given-names></name><address><email>paul.delmar@roche.com</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Klein</surname><given-names>Gregory</given-names></name><address><email>gregory.klein@roche.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Andjelkovic</surname><given-names>Mirjana</given-names></name><address><email>mirjana.andjelkovic@roche.com</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Dubois</surname><given-names>Bruno</given-names></name><address><email>bruno.dubois@psl.aphp.fr</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Boada</surname><given-names>Mercè</given-names></name><address><email>mboada@fundacioace.com</email></address><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Blennow</surname><given-names>Kaj</given-names></name><address><email>kaj.blennow@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Santarelli</surname><given-names>Luca</given-names></name><address><email>luca.santarelli@therachon.com</email></address><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fontoura</surname><given-names>Paulo</given-names></name><address><email>paulo.fontoura@roche.com</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><collab>for the SCarlet RoAD Investigators</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0534 4718</institution-id><institution-id institution-id-type="GRID">grid.418158.1</institution-id><institution>Product Development, </institution><institution>Neuroscience, Genentech Inc., </institution></institution-wrap>South San Francisco, CA USA </aff><aff id="Aff2"><label>2</label>MedDay Pharmaceuticals, Boston, MA USA </aff><aff id="Aff3"><label>3</label>Formerly Roche Translational &amp; Clinical Research Center, New York, NY USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution>VU University Medical Center, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>Institute of Neurology, UCL, </institution></institution-wrap>London, UK </aff><aff id="Aff6"><label>6</label>Roche Pharma Research and Early Development, NORD, Basel, Switzerland </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.419227.b</institution-id><institution>Roche Products Limited, </institution></institution-wrap>Welwyn Garden City, UK </aff><aff id="Aff8"><label>8</label>Roche Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center, Basel, Switzerland </aff><aff id="Aff9"><label>9</label>Clinical Pharmacology and Bioanalytical R&amp;D, Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland </aff><aff id="Aff10"><label>10</label>Alzheimer Institute and ICM, UMR-S975, Salpêtrière University Hospital, AP-HP, Pierre and Marie Curie University, Paris, France </aff><aff id="Aff11"><label>11</label>Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain </aff><aff id="Aff12"><label>12</label>Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain </aff><aff id="Aff13"><label>13</label>Formerly Roche Pharma Research and Early Development, NORD, Basel, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>9</volume><elocation-id>95</elocation-id><history><date date-type="received"><day>6</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>30</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>© The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="8757" xml_f="8767" txt_i="11" txt_f="21">Background</offsets></title><p id="Par1"><offsets xml_i="8788" xml_f="9053" txt_i="22" txt_f="287">Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab in prodromal Alzheimer’s disease (AD).</offsets></p></sec><sec><title><offsets xml_i="9075" xml_f="9082" txt_i="289" txt_f="296">Methods</offsets></title><p id="Par2"><offsets xml_i="9103" xml_f="9728" txt_i="297" txt_f="922">In this randomized, double-blind, placebo-controlled phase III study, we investigated gantenerumab over 2 years. Patients were randomized to gantenerumab 105 mg or 225 mg or placebo every 4 weeks by subcutaneous injection. The primary endpoint was the change from baseline to week 104 in Clinical Dementia Rating Sum of Boxes (CDR-SB) score. We evaluated treatment effects on cerebrospinal fluid biomarkers (all patients) and amyloid positron emission tomography (substudy). A futility analysis was performed once 50% of patients completed 2 years of treatment. Safety was assessed in patients who received at least one dose.</offsets></p></sec><sec><title><offsets xml_i="9750" xml_f="9757" txt_i="924" txt_f="931">Results</offsets></title><p id="Par3"><offsets xml_i="9778" xml_f="10310" txt_i="932" txt_f="1464">Of the 3089 patients screened, 797 were randomized. The study was halted early for futility; dosing was discontinued; and the study was unblinded. No differences between groups in the primary (least squares mean [95% CI] CDR-SB change from baseline 1.60 [1.28, 1.91], 1.69 [1.37, 2.01], and 1.73 [1.42, 2.04] for placebo, gantenerumab 105 mg, and gantenerumab 225 mg, respectively) or secondary clinical endpoints were observed. The incidence of generally asymptomatic amyloid-related imaging abnormalities increased in a dose- and </offsets><italic><offsets xml_i="10318" xml_f="10322" txt_i="1464" txt_f="1468">APOE</offsets></italic><offsets xml_i="10331" xml_f="10458" txt_i="1468" txt_f="1595"> ε4 genotype-dependent manner. Exploratory analyses suggested a dose-dependent drug effect on clinical and biomarker endpoints.</offsets></p></sec><sec><title><offsets xml_i="10480" xml_f="10491" txt_i="1597" txt_f="1608">Conclusions</offsets></title><p id="Par4"><offsets xml_i="10512" xml_f="10748" txt_i="1609" txt_f="1845">The study was stopped early for futility, but dose-dependent effects observed in exploratory analyses on select clinical and biomarker endpoints suggest that higher dosing with gantenerumab may be necessary to achieve clinical efficacy.</offsets></p></sec><sec><title><offsets xml_i="10770" xml_f="10788" txt_i="1847" txt_f="1865">Trial registration</offsets></title><p id="Par5"><offsets xml_i="10809" xml_f="10829" txt_i="1866" txt_f="1886">ClinicalTrials.gov, </offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01224106"><offsets xml_i="10920" xml_f="10931" txt_i="1886" txt_f="1897">NCT01224106</offsets></ext-link><offsets xml_i="10942" xml_f="10975" txt_i="1897" txt_f="1930">. Registered on October 14, 2010.</offsets></p></sec><sec><title><offsets xml_i="10997" xml_f="11030" txt_i="1932" txt_f="1965">Electronic supplementary material</offsets></title><p><offsets xml_i="11041" xml_f="11180" txt_i="1966" txt_f="2105">The online version of this article (doi:10.1186/s13195-017-0318-y) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Gantenerumab</kwd><kwd>Alzheimer’s disease</kwd><kwd>SCarlet RoAD</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007013</institution-id><institution>F. Hoffmann-La Roche</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="11821" xml_f="11831" txt_i="2114" txt_f="2124">Background</offsets></title><p id="Par35"><offsets xml_i="11853" xml_f="12146" txt_i="2125" txt_f="2418">Alzheimer’s disease (AD) is characterized by the presence of amyloid plaques and neurofibrillary tangles in the brain. Amyloid plaques are composed primarily of aggregated amyloid-beta (Aβ) peptide, which is deposited in the brain parenchyma, likely decades before clinical symptoms manifest [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="12178" xml_f="12179" txt_i="2418" txt_f="2419">1</offsets></xref><offsets xml_i="12186" xml_f="12303" txt_i="2419" txt_f="2536">]. Although the accumulation of presumably neurotoxic, aggregated Aβ is at the core of the amyloid hypothesis of AD [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="12335" xml_f="12336" txt_i="2536" txt_f="2537">2</offsets></xref><offsets xml_i="12343" xml_f="12784" txt_i="2537" txt_f="2978">], the specific process by which Aβ may lead to neuronal death remains unclear. Clinical progression has been reported to follow a predictable pattern, with patients transitioning through a preclinical stage, followed by a prodromal stage characterized by biomarker findings indicative of accumulating disease burden and cognitive symptoms not of sufficient severity to impact patient functioning, and eventually reaching the dementia stage.</offsets></p><p id="Par36"><offsets xml_i="12802" xml_f="13218" txt_i="2979" txt_f="3395">Prior to the initiation of the SCarlet RoAD study (NCT01224106; WN25203), researchers in most clinical trials identified patients with mild cognitive impairment (MCI) using clinical criteria, such as an episodic memory deficit or Clinical Dementia Rating (CDR) global score. Heterogeneity of patients with MCI has consistently been identified as a factor hampering the possibility of identifying a clinical benefit [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="13250" xml_f="13251" txt_i="3395" txt_f="3396">3</offsets></xref><offsets xml_i="13258" xml_f="13432" txt_i="3396" txt_f="3570">]. Subsequently, research criteria that included biomarkers of AD pathology were developed in an attempt to more specifically identify patients in the prodromal phase of AD [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="13464" xml_f="13465" txt_i="3570" txt_f="3571">4</offsets></xref><offsets xml_i="13472" xml_f="13474" txt_i="3571" txt_f="3573">, </offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="13506" xml_f="13507" txt_i="3573" txt_f="3574">5</offsets></xref><offsets xml_i="13514" xml_f="13563" txt_i="3574" txt_f="3623">]. Because cerebrospinal fluid (CSF) levels of Aβ</offsets><sub><offsets xml_i="13568" xml_f="13570" txt_i="3623" txt_f="3625">42</offsets></sub><offsets xml_i="13576" xml_f="13620" txt_i="3625" txt_f="3669"> have been found to be low in prodromal AD [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="13652" xml_f="13653" txt_i="3669" txt_f="3670">6</offsets></xref><offsets xml_i="13660" xml_f="13685" txt_i="3670" txt_f="3695">], CSF testing for low Aβ</offsets><sub><offsets xml_i="13690" xml_f="13692" txt_i="3695" txt_f="3697">42</offsets></sub><offsets xml_i="13698" xml_f="13759" txt_i="3697" txt_f="3758"> levels was required for inclusion in the SCarlet RoAD study.</offsets></p><p id="Par37"><offsets xml_i="13777" xml_f="13959" txt_i="3759" txt_f="3941">Gantenerumab (RO4909832, RG1450) is a human anti-Aβ monoclonal antibody that binds with high affinity to aggregated Aβ and promotes its removal by Fc receptor-mediated phagocytosis [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="13991" xml_f="13992" txt_i="3941" txt_f="3942">7</offsets></xref><offsets xml_i="13999" xml_f="14166" txt_i="3942" txt_f="4109">]. In a phase I study of 16 patients with mild to moderate AD, gantenerumab treatment resulted in a rapid reduction in brain amyloid load over the course of 6 months [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="14198" xml_f="14199" txt_i="4109" txt_f="4110">8</offsets></xref><offsets xml_i="14206" xml_f="14459" txt_i="4110" txt_f="4363">]. Gantenerumab intravenous (IV) doses of 60 mg (equivalent to ~ 100 mg subcutaneous [SC]) and 200 mg (equivalent to ~ 330 mg SC) given every 4 weeks were associated with dose-dependent cortical amyloid standardized uptake value ratio (SUVr) reduction [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="14491" xml_f="14492" txt_i="4363" txt_f="4364">8</offsets></xref><offsets xml_i="14499" xml_f="14538" txt_i="4364" txt_f="4403">] compared with placebo. At 200 mg IV, </offsets><italic><offsets xml_i="14546" xml_f="14568" txt_i="4403" txt_f="4425">apolipoprotein E (APOE</offsets></italic><offsets xml_i="14577" xml_f="14967" txt_i="4425" txt_f="4815">) ε4 genotype-dependent vasogenic edema (amyloid-related imaging abnormalities [ARIA]-E) and amyloid-related imaging abnormality microbleeds (ARIA-H) were detected, suggesting an optimal target dose for the investigation of efficacy above 100 mg but below 330 mg SC. Accordingly, gantenerumab SC doses of 105 mg and 225 mg given every 4 weeks were selected for the SCarlet RoAD study, with </offsets><italic><offsets xml_i="14975" xml_f="14979" txt_i="4815" txt_f="4819">APOE</offsets></italic><offsets xml_i="14988" xml_f="15565" txt_i="4819" txt_f="5396"> ε4 homozygous patients randomized to the lower dose or placebo only. SCarlet RoAD was the first phase III study in prodromal AD confirmed by CSF amyloid analysis with a single primary endpoint, the CDR Sum of Boxes (CDR-SB). The primary objective was to evaluate the effect of gantenerumab (105 and 225 mg) compared with placebo on CDR-SB in prodromal AD over the course of 2 years of treatment. In this paper, we report the efficacy, biomarker, and safety data available at the time of SCarlet RoAD futility analysis, including results of preplanned and exploratory analyses.</offsets></p></sec><sec id="Sec2"><title><offsets xml_i="15597" xml_f="15604" txt_i="5398" txt_f="5405">Methods</offsets></title><p id="Par38"><offsets xml_i="15626" xml_f="16104" txt_i="5406" txt_f="5884">SCarlet RoAD was a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 2-year study of gantenerumab in prodromal AD. The study was conducted globally across 128 sites. SCarlet RoAD was approved by individual institutional ethics committees or institutional review boards and was conducted in accordance with the principles of the Declaration of Helsinki and good clinical practice (GCP). Written informed consent was obtained from each patient.</offsets></p><sec id="Sec3"><title><offsets xml_i="16130" xml_f="16138" txt_i="5885" txt_f="5893">Patients</offsets></title><p id="Par39"><offsets xml_i="16160" xml_f="16999" txt_i="5894" txt_f="6733">A total of 3089 patients were screened for eligibility for this study. The screening period lasted up to 8 weeks, with rescreening permitted after ≥ 3 months for patients who did not meet select eligibility criteria. It was recommended that the first screening tests be the CDR, Free and Cued Selective Reminding Test (FCSRT), and Mini Mental State Examination (MMSE), in any order. CSF collection and magnetic resonance imaging (MRI) were conducted only after neuropsychological, electrocardiographic, and laboratory tests confirmed eligibility. Participation in an exploratory amyloid positron emission tomography (PET) substudy was optional and was not available at all sites. For patients in this substudy, a positive screening scan for amyloid PET was required and was performed once eligibility for the main study had been confirmed.</offsets></p><p id="Par40"><offsets xml_i="17017" xml_f="17129" txt_i="6734" txt_f="6846">Patients in SCarlet RoAD were 50–85 years of age and met International Working Group criteria for prodromal AD [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="17161" xml_f="17162" txt_i="6846" txt_f="6847">4</offsets></xref><offsets xml_i="17169" xml_f="17652" txt_i="6847" txt_f="7318">], with biomarker evidence of amyloid pathology and largely preserved functional abilities such that a diagnosis of dementia could not be made. Clinical status was documented by an MMSE score ≥ 24, a CDR global score of 0.5 with an accompanying memory box score of 0.5 or 1.0, abnormal memory function based on an FCSRT score of either &lt; 17 free recall, &lt; 40 total recall, or &lt; 20 free recall, and &lt; 42 total recall; a score ≤ 4 on the modified Hachinski Ischemic Scale [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="17684" xml_f="17685" txt_i="7318" txt_f="7319">9</offsets></xref><offsets xml_i="17692" xml_f="17856" txt_i="7319" txt_f="7483">]; and absence of depression documented by a score ≤ 6 on the Geriatric Depression Scale (GDS). Evidence of amyloid pathology was required as determined by a CSF Aβ</offsets><sub><offsets xml_i="17861" xml_f="17865" txt_i="7483" txt_f="7487">1–42</offsets></sub><offsets xml_i="17871" xml_f="17898" txt_i="7487" txt_f="7514"> level ≤ 600 ng/L (INNOTEST</offsets><sup><offsets xml_i="17903" xml_f="17904" txt_i="7514" txt_f="7515">®</offsets></sup><offsets xml_i="17910" xml_f="17913" txt_i="7515" txt_f="7518"> Aβ</offsets><sub><offsets xml_i="17918" xml_f="17922" txt_i="7518" txt_f="7522">1–42</offsets></sub><offsets xml_i="17928" xml_f="17957" txt_i="7522" txt_f="7551">; Fujirebio, Ghent, Belgium).</offsets></p><p id="Par41"><offsets xml_i="17975" xml_f="18530" txt_i="7552" txt_f="8107">Exclusion criteria were neurological disease other than AD, abnormal brain MRI at screening (including three or more microhemorrhages [1.5 T], two or more lacunar infarcts, extensive/confluent deep white matter lesions, or any space occupying lesions), a major psychiatric disorder, and a history of stroke or any clinically unstable medical illness. Symptomatic treatment with memantine or acetylcholinesterase inhibitors was not permitted at any time during the study; patients requiring such antidementia therapy were to be discontinued from the study.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="18562" xml_f="18587" txt_i="8109" txt_f="8134">Randomization and masking</offsets></title><p id="Par42"><offsets xml_i="18609" xml_f="18845" txt_i="8135" txt_f="8371">The planned sample size was 770, with patients meeting eligibility criteria randomized to treatment with placebo, gantenerumab 105 mg SC, or gantenerumab 225 mg SC every 4 weeks (ratio 2:1 for active placebo). Patients with zero or one </offsets><italic><offsets xml_i="18853" xml_f="18857" txt_i="8371" txt_f="8375">APOE</offsets></italic><offsets xml_i="18866" xml_f="18925" txt_i="8375" txt_f="8434"> ε4 allele were randomized to any treatment group, whereas </offsets><italic><offsets xml_i="18933" xml_f="18937" txt_i="8434" txt_f="8438">APOE</offsets></italic><offsets xml_i="18946" xml_f="19025" txt_i="8438" txt_f="8517"> ε4 homozygotes could be randomized only to placebo or gantenerumab 105 mg SC. </offsets><italic><offsets xml_i="19033" xml_f="19037" txt_i="8517" txt_f="8521">APOE</offsets></italic><offsets xml_i="19046" xml_f="19321" txt_i="8521" txt_f="8796"> ε4 status was blinded to sponsor, patient, and investigator. The algorithm for dynamic patient allocation to treatment was based on minimization with biased coin assignment. The randomization was stratified by PET substudy participation (participation vs nonparticipation), </offsets><italic><offsets xml_i="19329" xml_f="19333" txt_i="8796" txt_f="8800">APOE</offsets></italic><offsets xml_i="19342" xml_f="19594" txt_i="8800" txt_f="9052"> ε4 allele status (0 ε4 vs 1 ε4 vs 2 ε4), and region (Europe vs rest of world). The study was conducted in a double-blind manner. A potentially unblinded person was involved in the preparation of study medication but was not involved with patient care.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="19626" xml_f="19636" txt_i="9054" txt_f="9064">Procedures</offsets></title><p id="Par43"><offsets xml_i="19658" xml_f="19926" txt_i="9065" txt_f="9333">Treatment with placebo, gantenerumab 105 mg, or gantenerumab 225 mg was administered SC every 4 weeks in the abdomen. The gantenerumab drug product was manufactured by Roche Pharma AG (Grenzach-Wyhlen, Germany) in accordance with Roche standards and local regulations.</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="19958" xml_f="19975" txt_i="9335" txt_f="9352">Clinical outcomes</offsets></title><p id="Par44"><offsets xml_i="19997" xml_f="20070" txt_i="9353" txt_f="9426">The primary endpoint was the change from baseline in CDR-SB at week 104 [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="20103" xml_f="20105" txt_i="9426" txt_f="9428">10</offsets></xref><offsets xml_i="20112" xml_f="20704" txt_i="9428" txt_f="10020">]. Secondary endpoints included changes in cognition, behavior, and daily function over 104 weeks. Cognition was assessed using the 13-item Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog 13), the MMSE, a computerized cognitive battery (Cambridge Neuropsychological Test Automated Battery [CANTAB]), and the FCSRT. Behavior and daily functioning were assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q) and the Functional Activities Questionnaire (FAQ), respectively. Clinical assessments were carried out before the first dose and every 12 weeks thereafter.</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="20736" xml_f="20754" txt_i="10022" txt_f="10040">Biomarker outcomes</offsets></title><p id="Par45"><offsets xml_i="20776" xml_f="20878" txt_i="10041" txt_f="10143">Biomarker assessments included amyloid PET, brain volumes as measured by MRI, CSF concentrations of Aβ</offsets><sub><offsets xml_i="20883" xml_f="20887" txt_i="10143" txt_f="10147">1–42</offsets></sub><offsets xml_i="20893" xml_f="20962" txt_i="10147" txt_f="10216">, total tau (t-tau), phosphorylated tau 181 (p-tau), and neurogranin.</offsets></p><sec id="Sec8"><title><offsets xml_i="20988" xml_f="20999" txt_i="10217" txt_f="10228">Amyloid PET</offsets></title><p id="Par46"><offsets xml_i="21021" xml_f="21042" txt_i="10229" txt_f="10250">Participants in the [</offsets><sup><offsets xml_i="21047" xml_f="21049" txt_i="10250" txt_f="10252">18</offsets></sup><offsets xml_i="21055" xml_f="21731" txt_i="10252" txt_f="10928">F]florbetapir substudy underwent PET scanning at baseline and at weeks 20, 60, and 100. PET acquisition started 50 minutes postinjection, and three 5-minute frames were acquired. All PET data were corrected for radioactive decay, scatter, and attenuation. The data were also assessed for artefacts and patient motion. All further PET data processing was performed in PMOD (PMOD Technologies, Zürich, Switzerland). After motion correction and averaging of the three frames, the PET scan was coregistered to the cropped, skull-stripped screening MRI and normalized to the Montreal Neurological Institute space using the normalization parameters obtained from the MRI scan. The [</offsets><sup><offsets xml_i="21736" xml_f="21738" txt_i="10928" txt_f="10930">18</offsets></sup><offsets xml_i="21744" xml_f="21853" txt_i="10930" txt_f="11039">F]florbetapir global cortical signal was calculated as the volume-weighted, gray matter-masked average SUVr [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="21886" xml_f="21888" txt_i="11039" txt_f="11041">11</offsets></xref><offsets xml_i="21895" xml_f="22085" txt_i="11041" txt_f="11231">] of five bilateral cortical regions defined on the basis of Automated Anatomical Labeling template: anterior and posterior cingulate cortex, parietal, lateral temporal, and frontal cortex [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="22118" xml_f="22120" txt_i="11231" txt_f="11233">12</offsets></xref><offsets xml_i="22127" xml_f="22279" txt_i="11233" txt_f="11385">], using cerebellar cortex as the reference region for intensity normalization. Other reference regions investigated included whole cerebellum and pons.</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="22311" xml_f="22314" txt_i="11387" txt_f="11390">MRI</offsets></title><p id="Par47"><offsets xml_i="22336" xml_f="23038" txt_i="11391" txt_f="12093">MRI was performed using 1.5-T magnets. In exceptional circumstances, a 3-T magnet was accepted. MRI scans were obtained for subject screening and safety monitoring and to determine potential treatment effects on brain volumes. Each time an MRI scan was scheduled, we acquired near-isotropic 3D T1-weighted gradient echo, axial 5-mm T2*-weighted gradient echo with a minimum echo time of 20 milliseconds; T2-weighted spin-echo fluid-attenuated inversion recovery; and, if available, diffusion-weighted scans. Images were centrally quality-controlled and read by a neuroradiologist. Screening, week 48, and week 104 MRI scans were used for volumetric analysis of hippocampi, whole brain, and ventricles [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="23071" xml_f="23073" txt_i="12093" txt_f="12095">13</offsets></xref><offsets xml_i="23080" xml_f="23082" txt_i="12095" txt_f="12097">, </offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="23115" xml_f="23117" txt_i="12097" txt_f="12099">14</offsets></xref><offsets xml_i="23124" xml_f="23253" txt_i="12099" txt_f="12228">]. Hippocampal volume was assessed by trained technicians using manual tracing. Whole-brain volume change was measured using the </offsets><italic><offsets xml_i="23261" xml_f="23262" txt_i="12228" txt_f="12229">k</offsets></italic><offsets xml_i="23271" xml_f="23309" txt_i="12229" txt_f="12267">-means brain boundary shift integral [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="23342" xml_f="23344" txt_i="12267" txt_f="12269">14</offsets></xref><offsets xml_i="23351" xml_f="23440" txt_i="12269" txt_f="12358">]. Ventricular volume change was measured using the ventricular boundary shift integral [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="23473" xml_f="23475" txt_i="12358" txt_f="12360">13</offsets></xref><offsets xml_i="23482" xml_f="23484" txt_i="12360" txt_f="12362">].</offsets></p></sec><sec id="Sec10"><title><offsets xml_i="23517" xml_f="23520" txt_i="12364" txt_f="12367">CSF</offsets></title><p id="Par48"><offsets xml_i="23542" xml_f="23657" txt_i="12368" txt_f="12483">CSF was sampled at screening and at weeks 52 (optional) and 104. Screening samples were analyzed using INNOTEST® Aβ</offsets><sub><offsets xml_i="23662" xml_f="23666" txt_i="12483" txt_f="12487">1–42</offsets></sub><offsets xml_i="23672" xml_f="23806" txt_i="12487" txt_f="12621"> for eligibility assessment. For longitudinal analyses, CSF biomarkers from all time points were measured using the Elecsys® β-Amyloid</offsets><sub><offsets xml_i="23811" xml_f="23815" txt_i="12621" txt_f="12625">1–42</offsets></sub><offsets xml_i="23821" xml_f="23839" txt_i="12625" txt_f="12643">, t-tau, and p-tau</offsets><sub><offsets xml_i="23844" xml_f="23848" txt_i="12643" txt_f="12647">181P</offsets></sub><offsets xml_i="23854" xml_f="23917" txt_i="12647" txt_f="12710"> immunoassays (Roche Diagnostics GmbH, Rotkreuz, Switzerland) [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="23950" xml_f="23952" txt_i="12710" txt_f="12712">15</offsets></xref><offsets xml_i="23959" xml_f="24048" txt_i="12712" txt_f="12801">]. Neurogranin, a biomarker associated with synaptic dysfunction and degeneration in AD [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="24081" xml_f="24083" txt_i="12801" txt_f="12803">16</offsets></xref><offsets xml_i="24090" xml_f="24092" txt_i="12803" txt_f="12805">, </offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="24125" xml_f="24127" txt_i="12805" txt_f="12807">17</offsets></xref><offsets xml_i="24134" xml_f="24286" txt_i="12807" txt_f="12959">], was evaluated at the clinical neurochemistry laboratory of Dr. Kaj Blennow, Gothenburg, Sweden, using an in-house enzyme-linked immunosorbent assay [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="24319" xml_f="24321" txt_i="12959" txt_f="12961">18</offsets></xref><offsets xml_i="24328" xml_f="24330" txt_i="12961" txt_f="12963">].</offsets></p></sec></sec><sec id="Sec11"><title><offsets xml_i="24369" xml_f="24386" txt_i="12966" txt_f="12983">Safety monitoring</offsets></title><p id="Par49"><offsets xml_i="24408" xml_f="24835" txt_i="12984" txt_f="13411">Safety was evaluated by reports of adverse events, clinical laboratory testing (hematologic and serum chemistry, and urinalysis), vital sign assessments, physical and neurological examinations, electrocardiography, antidrug antibody titers, and brain MRI. MRI reads documented all ARIA-E and ARIA-H, as well as scoring of ARIA-E using the ARIA-E rating scale (scale range 0–60, with higher scores indicating greater severity) [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="24868" xml_f="24870" txt_i="13411" txt_f="13413">19</offsets></xref><offsets xml_i="24877" xml_f="25465" txt_i="13413" txt_f="14001">]. All ARIA were recorded as adverse events and additionally reviewed by an independent MRI committee, whose reports were shared regularly with the independent data monitoring committee (IDMC). Patients were queried about new central nervous system symptoms following the identification of an ARIA. Upon new ARIA-E findings, treatment was withheld. MRI was performed approximately every 4–8 weeks until the ARIA-E had resolved or clearly decreased and stabilized, upon which, treatment ensued at half the original dose. If a second ARIA-E occurred, treatment was permanently discontinued.</offsets></p><p id="Par50"><offsets xml_i="25483" xml_f="26026" txt_i="14002" txt_f="14545">Treatment modification and discontinuation due to ARIA-H was based on cumulative numbers of new events over a 12-month period: if more than four events, treatment was discontinued; if more than two (but less than or equal to four), the dose was halved. For patients on half-dose, treatment was to be discontinued if new ARIA-H events were greater than two since the dose was halved or within the past 12 months, whichever was shorter. Depressive and suicidal symptoms were assessed using the GDS and the Columbia Suicide Severity Rating Scale.</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="26059" xml_f="26079" txt_i="14547" txt_f="14567">Statistical analysis</offsets></title><p id="Par51"><offsets xml_i="26101" xml_f="26277" txt_i="14568" txt_f="14744">The sample size was calculated to allow ≥ 80% power to demonstrate an effect size of 0.35 on the primary endpoint (gantenerumab 225 mg vs placebo) at the type I error level of </offsets><italic><offsets xml_i="26285" xml_f="26286" txt_i="14744" txt_f="14745">p</offsets></italic><offsets xml_i="26295" xml_f="26493" txt_i="14745" txt_f="14943"> ≤ 0.05 (two-sided). Power calculations were based on simulations of the mixed-effects model repeated measurement (MMRM) analysis planned for statistical assessment of the primary efficacy variable.</offsets></p><p id="Par52"><offsets xml_i="26511" xml_f="26977" txt_i="14944" txt_f="15410">The primary efficacy outcome—mean change from baseline on CDR-SB at week 104—was assessed using MMRM analysis incorporating data up to 104 weeks of treatment. The model included the change from baseline in the CDR-SB score as the dependent variable. The effects in the model included independent variables of the fixed categorical effects of treatment, assessment weeks relative to the first dose of study medication (i.e., time), treatment-by-time interaction, and </offsets><italic><offsets xml_i="26985" xml_f="26989" txt_i="15410" txt_f="15414">APOE</offsets></italic><offsets xml_i="26998" xml_f="27806" txt_i="15414" txt_f="16222"> ε4 status (carrier vs noncarrier), along with continuous covariates of the baseline CDR-SB value and hippocampal volume at baseline. Time was treated as the repeated variable within a subject. Subject, treatment, and time were treated as class variables. An unstructured variance-covariance structure was applied to model the within-subject errors. The primary MMRM was applied to the CDR-SB, ADAS-Cog 13, MMSE, and FAQ endpoints, as well as other endpoints, including CANTAB, FCSRT, and NPI-Q. Change from baseline in PET SUVr was evaluated using an analysis of covariance model with baseline value and treatment as independent variables. A nonparametric Wilcoxon test was used for percentage change from baseline in CSF biomarkers to minimize the influence of potential outliers. All reported exploratory </offsets><italic><offsets xml_i="27814" xml_f="27815" txt_i="16222" txt_f="16223">p</offsets></italic><offsets xml_i="27824" xml_f="27968" txt_i="16223" txt_f="16367"> values refer to comparisons between placebo and each gantenerumab arm. Comparisons of the gantenerumab 225 mg and placebo arms did not include </offsets><italic><offsets xml_i="27976" xml_f="27980" txt_i="16367" txt_f="16371">APOE</offsets></italic><offsets xml_i="27989" xml_f="28126" txt_i="16371" txt_f="16508"> ε4 homozygote patients. The analysis population included all study participants who received at least one injection of study medication.</offsets></p><p id="Par53"><offsets xml_i="28144" xml_f="28570" txt_i="16509" txt_f="16932">An IDMC served as an independent group to examine all safety and efficacy data on a roughly quarterly basis. Rules for the preplanned futility analysis (50% patients reaching 2-year endpoint) were such that the IDMC would recommend study termination if the likelihood of achieving an effect size of 0.2 at the end of the study was &lt; 15% based on estimates from the prespecified MMRM analysis model for the primary endpoint.</offsets></p></sec><sec id="Sec13"><title><offsets xml_i="28603" xml_f="28629" txt_i="16934" txt_f="16960">Role of the funding source</offsets></title><p id="Par54"><offsets xml_i="28651" xml_f="29084" txt_i="16961" txt_f="17394">The sponsor designed the study in consultation with the academic authors. Data were gathered by the study investigators, analyzed by the sponsor, and interpreted in collaboration with the academic authors. All authors were involved in the development of the manuscript. The academic authors had full access to the study data and vouch for the accuracy and integrity of the data and the fidelity of this report to the study protocols.</offsets></p></sec></sec><sec id="Sec14"><title><offsets xml_i="29123" xml_f="29130" txt_i="17397" txt_f="17404">Results</offsets></title><sec id="Sec15"><title><offsets xml_i="29161" xml_f="29177" txt_i="17405" txt_f="17421">Study population</offsets></title><p id="Par55"><offsets xml_i="29199" xml_f="29656" txt_i="17422" txt_f="17879">Of 3089 screened patients, 797 (25.9%) were randomized and received at least one injection of study medication. At the time of the interim analysis, 316 had completed 2 years of treatment. An additional 278 were enrolled but had not completed 2 years of treatment, and 203 patients had discontinued treatment, with the most common reasons being adverse events, self- or legal guardian withdrawal of consent, or the initiation of symptomatic therapies (Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="29688" xml_f="29689" txt_i="17879" txt_f="17880">1</offsets></xref><offsets xml_i="29696" xml_f="29698" txt_i="17880" txt_f="17882">).</offsets><fig id="Fig1"><label><offsets xml_i="29720" xml_f="29726" txt_i="17882" txt_f="17888">Fig. 1</offsets></label><caption><p><offsets xml_i="29746" xml_f="29822" txt_i="17888" txt_f="17964">Enrollment, randomization, and 2-year completion in the SCarlet RoAD study. </offsets><italic><offsets xml_i="29830" xml_f="29834" txt_i="17964" txt_f="17968">AChE</offsets></italic><offsets xml_i="29843" xml_f="29864" txt_i="17968" txt_f="17989"> Acetylcholinesterase</offsets></p></caption><graphic xlink:href="13195_2017_318_Fig1_HTML" id="MO1"></graphic></fig><offsets xml_i="29950" xml_f="29951" txt_i="17990" txt_f="17991">
</offsets></p></sec><sec id="Sec16"><title><offsets xml_i="29984" xml_f="30008" txt_i="17993" txt_f="18017">Baseline characteristics</offsets></title><p id="Par56"><offsets xml_i="30030" xml_f="30143" txt_i="18018" txt_f="18131">There were no differences between the treatment arms with respect to age, sex, race, education, or weight (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="30177" xml_f="30178" txt_i="18131" txt_f="18132">1</offsets></xref><offsets xml_i="30185" xml_f="30237" txt_i="18132" txt_f="18184">). By design, there were no patients homozygous for </offsets><italic><offsets xml_i="30245" xml_f="30249" txt_i="18184" txt_f="18188">APOE</offsets></italic><offsets xml_i="30258" xml_f="30411" txt_i="18188" txt_f="18341"> ε4 in the gantenerumab 225 mg arm. There were no differences between treatment groups with respect to baseline clinical scores or CSF biomarkers (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="30445" xml_f="30446" txt_i="18341" txt_f="18342">1</offsets></xref><offsets xml_i="30453" xml_f="30455" txt_i="18342" txt_f="18344">).</offsets><table-wrap id="Tab1"><label><offsets xml_i="30484" xml_f="30491" txt_i="18344" txt_f="18351">Table 1</offsets></label><caption><p><offsets xml_i="30511" xml_f="30573" txt_i="18351" txt_f="18413">Baseline characteristics of patients in the SCarlet RoAD study</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><offsets xml_i="30651" xml_f="30659" txt_i="18414" txt_f="18422">Variable</offsets></th><th colspan="3"><offsets xml_i="30680" xml_f="30711" txt_i="18422" txt_f="18453">Intention-to-treat population (</offsets><italic><offsets xml_i="30719" xml_f="30720" txt_i="18453" txt_f="18454">n</offsets></italic><offsets xml_i="30729" xml_f="30736" txt_i="18454" txt_f="18461"> = 797)</offsets></th></tr><tr><th><offsets xml_i="30754" xml_f="30761" txt_i="18461" txt_f="18468">Placebo</offsets><break></break><offsets xml_i="30776" xml_f="30777" txt_i="18468" txt_f="18469">(</offsets><italic><offsets xml_i="30785" xml_f="30786" txt_i="18469" txt_f="18470">n</offsets></italic><offsets xml_i="30795" xml_f="30802" txt_i="18470" txt_f="18477"> = 266)</offsets></th><th><offsets xml_i="30811" xml_f="30830" txt_i="18477" txt_f="18496">Gantenerumab 105 mg</offsets><break></break><offsets xml_i="30845" xml_f="30846" txt_i="18496" txt_f="18497">(</offsets><italic><offsets xml_i="30854" xml_f="30855" txt_i="18497" txt_f="18498">n</offsets></italic><offsets xml_i="30864" xml_f="30871" txt_i="18498" txt_f="18505"> = 271)</offsets></th><th><offsets xml_i="30880" xml_f="30899" txt_i="18505" txt_f="18524">Gantenerumab 225 mg</offsets><break></break><offsets xml_i="30914" xml_f="30915" txt_i="18524" txt_f="18525">(</offsets><italic><offsets xml_i="30923" xml_f="30924" txt_i="18525" txt_f="18526">n</offsets></italic><offsets xml_i="30933" xml_f="30940" txt_i="18526" txt_f="18533"> = 260)</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="30973" xml_f="30994" txt_i="18533" txt_f="18554">Age, years, mean (SD)</offsets></td><td><offsets xml_i="31003" xml_f="31013" txt_i="18555" txt_f="18565">69.5 (7.5)</offsets></td><td><offsets xml_i="31022" xml_f="31032" txt_i="18566" txt_f="18576">70.3 (7.0)</offsets></td><td><offsets xml_i="31041" xml_f="31051" txt_i="18577" txt_f="18587">71.3 (7.1)</offsets></td></tr><tr><td><offsets xml_i="31069" xml_f="31096" txt_i="18588" txt_f="18615">Education, years, mean (SD)</offsets></td><td><offsets xml_i="31105" xml_f="31110" txt_i="18616" txt_f="18621">89.8%</offsets></td><td><offsets xml_i="31119" xml_f="31124" txt_i="18622" txt_f="18627">93.0%</offsets></td><td><offsets xml_i="31133" xml_f="31138" txt_i="18628" txt_f="18633">91.9%</offsets></td></tr><tr><td><offsets xml_i="31156" xml_f="31177" txt_i="18634" txt_f="18655">Weight, kg, mean (SD)</offsets></td><td><offsets xml_i="31186" xml_f="31196" txt_i="18656" txt_f="18666">12.6 (4.3)</offsets></td><td><offsets xml_i="31205" xml_f="31215" txt_i="18667" txt_f="18677">12.9 (4.8)</offsets></td><td><offsets xml_i="31224" xml_f="31234" txt_i="18678" txt_f="18688">12.1 (4.5)</offsets></td></tr><tr><td><offsets xml_i="31252" xml_f="31253" txt_i="18689" txt_f="18690">
</offsets><italic><offsets xml_i="31261" xml_f="31265" txt_i="18690" txt_f="18694">APOE</offsets></italic><offsets xml_i="31274" xml_f="31289" txt_i="18694" txt_f="18709"> ε4 genotype, %</offsets><sup><offsets xml_i="31294" xml_f="31295" txt_i="18709" txt_f="18710">a</offsets></sup><offsets xml_i="31301" xml_f="31302" txt_i="18710" txt_f="18711">
</offsets></td><td><offsets xml_i="31311" xml_f="31322" txt_i="18712" txt_f="18723">69.8 (12.9)</offsets></td><td><offsets xml_i="31331" xml_f="31342" txt_i="18724" txt_f="18735">70.5 (13.6)</offsets></td><td><offsets xml_i="31351" xml_f="31362" txt_i="18736" txt_f="18747">70.1 (12.5)</offsets></td></tr><tr><td><offsets xml_i="31380" xml_f="31381" txt_i="18748" txt_f="18749"> </offsets></td><td><offsets xml_i="31390" xml_f="31395" txt_i="18750" txt_f="18755">29.7%</offsets></td><td><offsets xml_i="31404" xml_f="31409" txt_i="18756" txt_f="18761">21.0%</offsets></td><td><offsets xml_i="31418" xml_f="31423" txt_i="18762" txt_f="18767">38.5%</offsets></td></tr><tr><td><offsets xml_i="31441" xml_f="31445" txt_i="18768" txt_f="18772"> 1ε4</offsets></td><td><offsets xml_i="31454" xml_f="31459" txt_i="18773" txt_f="18778">50.4%</offsets></td><td><offsets xml_i="31468" xml_f="31473" txt_i="18779" txt_f="18784">41.0%</offsets></td><td><offsets xml_i="31482" xml_f="31487" txt_i="18785" txt_f="18790">61.5%</offsets></td></tr><tr><td><offsets xml_i="31505" xml_f="31509" txt_i="18791" txt_f="18795"> 2ε4</offsets></td><td><offsets xml_i="31518" xml_f="31523" txt_i="18796" txt_f="18801">19.9%</offsets></td><td><offsets xml_i="31532" xml_f="31537" txt_i="18802" txt_f="18807">38.0%</offsets></td><td><offsets xml_i="31546" xml_f="31547" txt_i="18808" txt_f="18809">–</offsets></td></tr><tr><td colspan="4"><offsets xml_i="31577" xml_f="31592" txt_i="18810" txt_f="18825">Clinical scores</offsets></td></tr><tr><td><offsets xml_i="31610" xml_f="31634" txt_i="18826" txt_f="18850"> CDR-SB, mean score (SD)</offsets></td><td><offsets xml_i="31643" xml_f="31652" txt_i="18851" txt_f="18860">2.1 (1.0)</offsets></td><td><offsets xml_i="31661" xml_f="31670" txt_i="18861" txt_f="18870">2.2 (1.0)</offsets></td><td><offsets xml_i="31679" xml_f="31688" txt_i="18871" txt_f="18880">2.0 (0.9)</offsets></td></tr><tr><td><offsets xml_i="31706" xml_f="31735" txt_i="18881" txt_f="18910"> ADAS-Cog 13, mean score (SD)</offsets></td><td><offsets xml_i="31744" xml_f="31754" txt_i="18911" txt_f="18921">23.5 (7.2)</offsets></td><td><offsets xml_i="31763" xml_f="31773" txt_i="18922" txt_f="18932">23.1 (6.9)</offsets></td><td><offsets xml_i="31782" xml_f="31792" txt_i="18933" txt_f="18943">23.0 (6.2)</offsets></td></tr><tr><td><offsets xml_i="31810" xml_f="31831" txt_i="18944" txt_f="18965"> FAQ, mean score (SD)</offsets></td><td><offsets xml_i="31840" xml_f="31849" txt_i="18966" txt_f="18975">4.9 (4.3)</offsets></td><td><offsets xml_i="31858" xml_f="31867" txt_i="18976" txt_f="18985">4.6 (3.9)</offsets></td><td><offsets xml_i="31876" xml_f="31885" txt_i="18986" txt_f="18995">4.8 (4.3)</offsets></td></tr><tr><td><offsets xml_i="31903" xml_f="31939" txt_i="18996" txt_f="19032"> FCSRT-Total Recall, mean score (SD)</offsets></td><td><offsets xml_i="31948" xml_f="31959" txt_i="19033" txt_f="19044">29.3 (10.8)</offsets></td><td><offsets xml_i="31968" xml_f="31979" txt_i="19045" txt_f="19056">28.3 (10.8)</offsets></td><td><offsets xml_i="31988" xml_f="31999" txt_i="19057" txt_f="19068">30.5 (10.4)</offsets></td></tr><tr><td><offsets xml_i="32017" xml_f="32039" txt_i="19069" txt_f="19091"> MMSE, mean score (SD)</offsets></td><td><offsets xml_i="32048" xml_f="32058" txt_i="19092" txt_f="19102">25.7 (2.1)</offsets></td><td><offsets xml_i="32067" xml_f="32077" txt_i="19103" txt_f="19113">25.7 (2.3)</offsets></td><td><offsets xml_i="32086" xml_f="32096" txt_i="19114" txt_f="19124">25.7 (2.2)</offsets></td></tr><tr><td colspan="4"><offsets xml_i="32126" xml_f="32140" txt_i="19125" txt_f="19139">CSF biomarkers</offsets></td></tr><tr><td><offsets xml_i="32158" xml_f="32161" txt_i="19140" txt_f="19143"> Aβ</offsets><sub><offsets xml_i="32166" xml_f="32168" txt_i="19143" txt_f="19145">42</offsets></sub><offsets xml_i="32174" xml_f="32192" txt_i="19145" txt_f="19163">, pg/ml, mean (SD)</offsets></td><td><offsets xml_i="32201" xml_f="32214" txt_i="19164" txt_f="19177">487.8 (170.4)</offsets></td><td><offsets xml_i="32223" xml_f="32236" txt_i="19178" txt_f="19191">475.3 (142.2)</offsets></td><td><offsets xml_i="32245" xml_f="32258" txt_i="19192" txt_f="19205">511.8 (172.0)</offsets></td></tr><tr><td><offsets xml_i="32276" xml_f="32300" txt_i="19206" txt_f="19230"> t-tau, pg/ml, mean (SD)</offsets></td><td><offsets xml_i="32309" xml_f="32322" txt_i="19231" txt_f="19244">556.3 (203.8)</offsets></td><td><offsets xml_i="32331" xml_f="32344" txt_i="19245" txt_f="19258">563.2 (239.1)</offsets></td><td><offsets xml_i="32353" xml_f="32366" txt_i="19259" txt_f="19272">544.5 (220.5)</offsets></td></tr><tr><td><offsets xml_i="32384" xml_f="32408" txt_i="19273" txt_f="19297"> p-tau, pg/ml, mean (SD)</offsets></td><td><offsets xml_i="32417" xml_f="32428" txt_i="19298" txt_f="19309">84.0 (31.4)</offsets></td><td><offsets xml_i="32437" xml_f="32448" txt_i="19310" txt_f="19321">86.3 (39.5)</offsets></td><td><offsets xml_i="32457" xml_f="32468" txt_i="19322" txt_f="19333">82.5 (34.2)</offsets></td></tr><tr><td><offsets xml_i="32486" xml_f="32516" txt_i="19334" txt_f="19364"> Neurogranin, pg/ml, mean (SD)</offsets></td><td><offsets xml_i="32525" xml_f="32538" txt_i="19365" txt_f="19378">474.8 (260.7)</offsets></td><td><offsets xml_i="32547" xml_f="32560" txt_i="19379" txt_f="19392">500.5 (270.0)</offsets></td><td><offsets xml_i="32569" xml_f="32582" txt_i="19393" txt_f="19406">484.9 (293.9)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="32628" xml_f="32629" txt_i="19407" txt_f="19408">
</offsets><italic><offsets xml_i="32637" xml_f="32660" txt_i="19408" txt_f="19431">Abbreviations: ADAS-Cog</offsets></italic><offsets xml_i="32669" xml_f="32727" txt_i="19431" txt_f="19489"> Alzheimer’s Disease Assessment Scale–Cognitive subscale, </offsets><italic><offsets xml_i="32735" xml_f="32739" txt_i="19489" txt_f="19493">APOE</offsets></italic><offsets xml_i="32748" xml_f="32767" txt_i="19493" txt_f="19512"> Apolipoprotein E, </offsets><italic><offsets xml_i="32775" xml_f="32781" txt_i="19512" txt_f="19518">CDR-SB</offsets></italic><offsets xml_i="32790" xml_f="32830" txt_i="19518" txt_f="19558"> Clinical Dementia Rating Sum of Boxes, </offsets><italic><offsets xml_i="32838" xml_f="32841" txt_i="19558" txt_f="19561">CSF</offsets></italic><offsets xml_i="32850" xml_f="32872" txt_i="19561" txt_f="19583"> Cerebrospinal fluid, </offsets><italic><offsets xml_i="32880" xml_f="32883" txt_i="19583" txt_f="19586">FAQ</offsets></italic><offsets xml_i="32892" xml_f="32930" txt_i="19586" txt_f="19624"> Functional Activities Questionnaire, </offsets><italic><offsets xml_i="32938" xml_f="32943" txt_i="19624" txt_f="19629">FCSRT</offsets></italic><offsets xml_i="32952" xml_f="32993" txt_i="19629" txt_f="19670"> Free and Cued Selective Reminding Test, </offsets><italic><offsets xml_i="33001" xml_f="33005" txt_i="19670" txt_f="19674">MMSE</offsets></italic><offsets xml_i="33014" xml_f="33044" txt_i="19674" txt_f="19704"> Mini Mental State Examination</offsets></p><p><offsets xml_i="33051" xml_f="33052" txt_i="19705" txt_f="19706">
</offsets><sup><offsets xml_i="33057" xml_f="33058" txt_i="19706" txt_f="19707">a</offsets></sup><offsets xml_i="33064" xml_f="33089" txt_i="19707" txt_f="19732">By design, there were no </offsets><italic><offsets xml_i="33097" xml_f="33101" txt_i="19732" txt_f="19736">APOE</offsets></italic><offsets xml_i="33110" xml_f="33154" txt_i="19736" txt_f="19780"> 2ε4 patients in the gantenerumab 225 mg arm</offsets></p></table-wrap-foot></table-wrap><offsets xml_i="33189" xml_f="33190" txt_i="19781" txt_f="19782">
</offsets></p><p id="Par57"><offsets xml_i="33208" xml_f="33477" txt_i="19783" txt_f="20052">The baseline demographics and disease characteristics of patients in the PET substudy and those of patients with CSF biomarker data at week 104 did not substantially differ from the overall study population and were well balanced across treatment arms (data not shown).</offsets></p></sec><sec id="Sec17"><title><offsets xml_i="33510" xml_f="33526" txt_i="20054" txt_f="20070">Interim analysis</offsets></title><p id="Par58"><offsets xml_i="33548" xml_f="34274" txt_i="20071" txt_f="20797">At the preplanned interim analysis, the prespecified stopping criterion for futility was met. With an estimated value of 6%, the predictive probability of success was below the prespecified cutoff of 15%. There was no difference between the placebo arm and either of the gantenerumab treatment arms in the primary endpoint (change from baseline in CDR-SB score at 2 years). The IDMC recommended terminating the trial for futility based on a lack of efficacy and unrelated to safety findings or concerns. This recommendation was endorsed by the sponsor’s review board. Following this interim analysis, dosing of study drug was halted, and the study was unblinded. Data collected up to the time of unblinding are presented here.</offsets></p><p id="Par59"><offsets xml_i="34292" xml_f="34343" txt_i="20798" txt_f="20849">Therefore, all analyses presented below, including </offsets><italic><offsets xml_i="34351" xml_f="34352" txt_i="20849" txt_f="20850">p</offsets></italic><offsets xml_i="34361" xml_f="34459" txt_i="20850" txt_f="20948"> values, should be considered as strictly descriptive and exploratory. In this context, no formal </offsets><italic><offsets xml_i="34467" xml_f="34468" txt_i="20948" txt_f="20949">p</offsets></italic><offsets xml_i="34477" xml_f="34594" txt_i="20949" txt_f="21066"> value correction for multiple testing was applied, but multiplicity was considered in the interpretation of results.</offsets></p></sec><sec id="Sec18"><title><offsets xml_i="34627" xml_f="34656" txt_i="21068" txt_f="21097">Exploratory efficacy analysis</offsets></title><p id="Par60"><offsets xml_i="34678" xml_f="34848" txt_i="21098" txt_f="21268">In addition to the primary endpoint (CDR-SB), the analysis of secondary cognitive, functional, and behavioral endpoints also showed no treatment effect at 2 years (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="34882" xml_f="34883" txt_i="21268" txt_f="21269">2</offsets></xref><offsets xml_i="34890" xml_f="34897" txt_i="21269" txt_f="21276">, Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="34929" xml_f="34931" txt_i="21276" txt_f="21278">2a</offsets></xref><offsets xml_i="34938" xml_f="34943" txt_i="21278" txt_f="21283"> and </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="34975" xml_f="34976" txt_i="21283" txt_f="21284">b</offsets></xref><offsets xml_i="34983" xml_f="35034" txt_i="21284" txt_f="21335">), which is further illustrated by all exploratory </offsets><italic><offsets xml_i="35042" xml_f="35043" txt_i="21335" txt_f="21336">p</offsets></italic><offsets xml_i="35052" xml_f="35143" txt_i="21336" txt_f="21424"> values from the MMRM applied to CDR-SB, ADAS-Cog 13, MMSE, and FAQ being &gt; 0.05 (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="35177" xml_f="35178" txt_i="21424" txt_f="21425">2</offsets></xref><offsets xml_i="35185" xml_f="35297" txt_i="21425" txt_f="21537">). FCSRT with Immediate Recall total recall, CANTAB, and NPI-Q data showed no treatment effect (data not shown).</offsets><table-wrap id="Tab2"><label><offsets xml_i="35326" xml_f="35333" txt_i="21537" txt_f="21544">Table 2</offsets></label><caption><p><offsets xml_i="35353" xml_f="35486" txt_i="21544" txt_f="21677">Least squares mean change in primary and secondary clinical outcomes in mixed-effects model repeated measurement statistical analysis</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><offsets xml_i="35564" xml_f="35575" txt_i="21678" txt_f="21689">At week 104</offsets></th><th><offsets xml_i="35584" xml_f="35591" txt_i="21689" txt_f="21696">Placebo</offsets></th><th colspan="2"><offsets xml_i="35612" xml_f="35631" txt_i="21696" txt_f="21715">Gantenerumab 105 mg</offsets></th><th colspan="2"><offsets xml_i="35652" xml_f="35671" txt_i="21715" txt_f="21734">Gantenerumab 225 mg</offsets></th></tr><tr><th><offsets xml_i="35689" xml_f="35696" txt_i="21734" txt_f="21741">LS mean</offsets><break></break><offsets xml_i="35711" xml_f="35719" txt_i="21741" txt_f="21749">(95% CI)</offsets></th><th><offsets xml_i="35728" xml_f="35735" txt_i="21749" txt_f="21756">LS mean</offsets><break></break><offsets xml_i="35750" xml_f="35758" txt_i="21756" txt_f="21764">(95% CI)</offsets></th><th><offsets xml_i="35767" xml_f="35768" txt_i="21764" txt_f="21765">
</offsets><italic><offsets xml_i="35776" xml_f="35777" txt_i="21765" txt_f="21766">p</offsets></italic><offsets xml_i="35786" xml_f="35803" txt_i="21766" txt_f="21783"> Value vs placebo</offsets></th><th><offsets xml_i="35812" xml_f="35819" txt_i="21783" txt_f="21790">LS mean</offsets><break></break><offsets xml_i="35834" xml_f="35842" txt_i="21790" txt_f="21798">(95% CI)</offsets></th><th><offsets xml_i="35851" xml_f="35852" txt_i="21798" txt_f="21799">
</offsets><italic><offsets xml_i="35860" xml_f="35861" txt_i="21799" txt_f="21800">p</offsets></italic><offsets xml_i="35870" xml_f="35887" txt_i="21800" txt_f="21817"> Value vs placebo</offsets></th></tr></thead><tbody><tr><td colspan="6"><offsets xml_i="35932" xml_f="35948" txt_i="21817" txt_f="21833">Primary endpoint</offsets></td></tr><tr><td colspan="6"><offsets xml_i="35978" xml_f="35985" txt_i="21834" txt_f="21841"> CDR-SB</offsets></td></tr><tr><td><offsets xml_i="36003" xml_f="36025" txt_i="21842" txt_f="21864">  Change from baseline</offsets></td><td><offsets xml_i="36034" xml_f="36051" txt_i="21865" txt_f="21882">1.60 (1.28, 1.91)</offsets></td><td><offsets xml_i="36060" xml_f="36077" txt_i="21883" txt_f="21900">1.69 (1.37, 2.01)</offsets></td><td><offsets xml_i="36086" xml_f="36087" txt_i="21901" txt_f="21902">–</offsets></td><td><offsets xml_i="36096" xml_f="36113" txt_i="21903" txt_f="21920">1.73 (1.42, 2.04)</offsets></td><td><offsets xml_i="36122" xml_f="36123" txt_i="21921" txt_f="21922">–</offsets></td></tr><tr><td><offsets xml_i="36141" xml_f="36166" txt_i="21923" txt_f="21948">  Difference from placebo</offsets></td><td><offsets xml_i="36175" xml_f="36176" txt_i="21949" txt_f="21950">–</offsets></td><td><offsets xml_i="36185" xml_f="36203" txt_i="21951" txt_f="21969">0.10 (−0.35, 0.54)</offsets></td><td><offsets xml_i="36212" xml_f="36216" txt_i="21970" txt_f="21974">0.67</offsets></td><td><offsets xml_i="36225" xml_f="36243" txt_i="21975" txt_f="21993">0.18 (−0.28, 0.63)</offsets></td><td><offsets xml_i="36252" xml_f="36256" txt_i="21994" txt_f="21998">0.45</offsets></td></tr><tr><td colspan="6"><offsets xml_i="36286" xml_f="36304" txt_i="21999" txt_f="22017">Secondary endpoint</offsets></td></tr><tr><td colspan="6"><offsets xml_i="36334" xml_f="36346" txt_i="22018" txt_f="22030"> ADAS-Cog 13</offsets></td></tr><tr><td><offsets xml_i="36364" xml_f="36386" txt_i="22031" txt_f="22053">  Change from baseline</offsets></td><td><offsets xml_i="36395" xml_f="36412" txt_i="22054" txt_f="22071">5.77 (4.54, 6.99)</offsets></td><td><offsets xml_i="36421" xml_f="36438" txt_i="22072" txt_f="22089">5.14 (3.91, 6.38)</offsets></td><td><offsets xml_i="36447" xml_f="36448" txt_i="22090" txt_f="22091">–</offsets></td><td><offsets xml_i="36457" xml_f="36474" txt_i="22092" txt_f="22109">5.54 (4.21, 6.87)</offsets></td><td><offsets xml_i="36483" xml_f="36484" txt_i="22110" txt_f="22111">–</offsets></td></tr><tr><td><offsets xml_i="36502" xml_f="36527" txt_i="22112" txt_f="22137">  Difference from placebo</offsets></td><td><offsets xml_i="36536" xml_f="36537" txt_i="22138" txt_f="22139">–</offsets></td><td><offsets xml_i="36546" xml_f="36565" txt_i="22140" txt_f="22159">−0.62 (−2.34, 1.09)</offsets></td><td><offsets xml_i="36574" xml_f="36578" txt_i="22160" txt_f="22164">0.48</offsets></td><td><offsets xml_i="36587" xml_f="36606" txt_i="22165" txt_f="22184">−0.27 (−2.23, 1.70)</offsets></td><td><offsets xml_i="36615" xml_f="36619" txt_i="22185" txt_f="22189">0.79</offsets></td></tr><tr><td colspan="6"><offsets xml_i="36649" xml_f="36653" txt_i="22190" txt_f="22194"> FAQ</offsets></td></tr><tr><td><offsets xml_i="36671" xml_f="36693" txt_i="22195" txt_f="22217">  Change from baseline</offsets></td><td><offsets xml_i="36702" xml_f="36719" txt_i="22218" txt_f="22235">4.70 (3.71, 5.68)</offsets></td><td><offsets xml_i="36728" xml_f="36745" txt_i="22236" txt_f="22253">5.93 (4.93, 6.93)</offsets></td><td><offsets xml_i="36754" xml_f="36755" txt_i="22254" txt_f="22255">–</offsets></td><td><offsets xml_i="36764" xml_f="36781" txt_i="22256" txt_f="22273">4.57 (3.58, 5.55)</offsets></td><td><offsets xml_i="36790" xml_f="36791" txt_i="22274" txt_f="22275">–</offsets></td></tr><tr><td><offsets xml_i="36809" xml_f="36834" txt_i="22276" txt_f="22301">  Difference from placebo</offsets></td><td><offsets xml_i="36843" xml_f="36844" txt_i="22302" txt_f="22303">–</offsets></td><td><offsets xml_i="36853" xml_f="36871" txt_i="22304" txt_f="22322">1.23 (−0.16, 2.62)</offsets></td><td><offsets xml_i="36880" xml_f="36884" txt_i="22323" txt_f="22327">0.08</offsets></td><td><offsets xml_i="36893" xml_f="36912" txt_i="22328" txt_f="22347">−0.27 (−1.72, 1.18)</offsets></td><td><offsets xml_i="36921" xml_f="36925" txt_i="22348" txt_f="22352">0.72</offsets></td></tr><tr><td colspan="6"><offsets xml_i="36955" xml_f="36960" txt_i="22353" txt_f="22358"> MMSE</offsets></td></tr><tr><td><offsets xml_i="36978" xml_f="37000" txt_i="22359" txt_f="22381">  Change from baseline</offsets></td><td><offsets xml_i="37009" xml_f="37029" txt_i="22382" txt_f="22402">−2.93 (−3.50, −2.35)</offsets></td><td><offsets xml_i="37038" xml_f="37058" txt_i="22403" txt_f="22423">−3.02 (−3.60, −2.44)</offsets></td><td><offsets xml_i="37067" xml_f="37068" txt_i="22424" txt_f="22425">–</offsets></td><td><offsets xml_i="37077" xml_f="37097" txt_i="22426" txt_f="22446">−2.73 (−3.33, −2.14)</offsets></td><td><offsets xml_i="37106" xml_f="37107" txt_i="22447" txt_f="22448">–</offsets></td></tr><tr><td><offsets xml_i="37125" xml_f="37150" txt_i="22449" txt_f="22474">  Difference from placebo</offsets></td><td><offsets xml_i="37159" xml_f="37160" txt_i="22475" txt_f="22476">–</offsets></td><td><offsets xml_i="37169" xml_f="37188" txt_i="22477" txt_f="22496">−0.10 (−0.90, 0.71)</offsets></td><td><offsets xml_i="37197" xml_f="37201" txt_i="22497" txt_f="22501">0.81</offsets></td><td><offsets xml_i="37210" xml_f="37228" txt_i="22502" txt_f="22520">0.34 (−0.54, 1.22)</offsets></td><td><offsets xml_i="37237" xml_f="37241" txt_i="22521" txt_f="22525">0.45</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="37287" xml_f="37288" txt_i="22526" txt_f="22527">
</offsets><italic><offsets xml_i="37296" xml_f="37322" txt_i="22527" txt_f="22553">Abbreviations: ADAS-Cog 13</offsets></italic><offsets xml_i="37331" xml_f="37389" txt_i="22553" txt_f="22611"> Alzheimer’s Disease Assessment Scale–Cognitive subscale, </offsets><italic><offsets xml_i="37397" xml_f="37403" txt_i="22611" txt_f="22617">CDR-SB</offsets></italic><offsets xml_i="37412" xml_f="37452" txt_i="22617" txt_f="22657"> Clinical Dementia Rating Sum of Boxes, </offsets><italic><offsets xml_i="37460" xml_f="37463" txt_i="22657" txt_f="22660">FAQ</offsets></italic><offsets xml_i="37472" xml_f="37510" txt_i="22660" txt_f="22698"> Functional Activities Questionnaire, </offsets><italic><offsets xml_i="37518" xml_f="37520" txt_i="22698" txt_f="22700">LS</offsets></italic><offsets xml_i="37529" xml_f="37545" txt_i="22700" txt_f="22716"> Least squares, </offsets><italic><offsets xml_i="37553" xml_f="37557" txt_i="22716" txt_f="22720">MMSE</offsets></italic><offsets xml_i="37566" xml_f="37596" txt_i="22720" txt_f="22750"> Mini Mental State Examination</offsets></p></table-wrap-foot></table-wrap><offsets xml_i="37631" xml_f="37632" txt_i="22751" txt_f="22752">
</offsets><fig id="Fig2"><label><offsets xml_i="37654" xml_f="37660" txt_i="22752" txt_f="22758">Fig. 2</offsets></label><caption><p><offsets xml_i="37680" xml_f="37741" txt_i="22758" txt_f="22819">Least squares mean (±95% CI) change from baseline in CDR-SB (</offsets><bold><offsets xml_i="37747" xml_f="37748" txt_i="22819" txt_f="22820">a</offsets></bold><offsets xml_i="37755" xml_f="37780" txt_i="22820" txt_f="22845">) and ADAS-Cog 13 score (</offsets><bold><offsets xml_i="37786" xml_f="37787" txt_i="22845" txt_f="22846">b</offsets></bold><offsets xml_i="37794" xml_f="37797" txt_i="22846" txt_f="22849">). </offsets><italic><offsets xml_i="37805" xml_f="37811" txt_i="22849" txt_f="22855">CDR-SB</offsets></italic><offsets xml_i="37820" xml_f="37860" txt_i="22855" txt_f="22895"> Clinical Dementia Rating Sum of Boxes, </offsets><italic><offsets xml_i="37868" xml_f="37879" txt_i="22895" txt_f="22906">ADAS-Cog 13</offsets></italic><offsets xml_i="37888" xml_f="37946" txt_i="22906" txt_f="22964"> Alzheimer’s Disease Assessment Scale–Cognitive subscale, </offsets><italic><offsets xml_i="37954" xml_f="37956" txt_i="22964" txt_f="22966">LS</offsets></italic><offsets xml_i="37965" xml_f="37979" txt_i="22966" txt_f="22980"> Least squares</offsets></p></caption><graphic xlink:href="13195_2017_318_Fig2_HTML" id="MO2"></graphic></fig><offsets xml_i="38065" xml_f="38066" txt_i="22981" txt_f="22982">
</offsets></p></sec><sec id="Sec19"><title><offsets xml_i="38099" xml_f="38129" txt_i="22984" txt_f="23014">Exploratory biomarker analysis</offsets></title><p id="Par61"><offsets xml_i="38151" xml_f="38380" txt_i="23015" txt_f="23244">Exploratory biomarker analyses suggested a dose-dependent effect of gantenerumab on brain amyloid load as measured by PET, as well as on downstream biomarkers of neural and synaptic degeneration (CSF tau species and neurogranin).</offsets></p><sec id="Sec20"><title><offsets xml_i="38407" xml_f="38418" txt_i="23245" txt_f="23256">Amyloid PET</offsets></title><p id="Par62"><offsets xml_i="38440" xml_f="38829" txt_i="23257" txt_f="23646">There were 115 subjects with PET data at baseline, of whom 55 had PET data at the end of 2 years of study treatment. The mean cortical composite PET SUVr at baseline using the prespecified mean cerebellar gray reference region was 1.68, 1.65, and 1.62 for the placebo, 105-mg, and 225-mg dose groups, respectively. The effect of gantenerumab on PET SUVr was dose- and time-dependent (Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="38861" xml_f="38862" txt_i="23646" txt_f="23647">3</offsets></xref><offsets xml_i="38869" xml_f="38959" txt_i="23647" txt_f="23737">). PET SUVr was reduced from baseline by an average 4.8% (absolute mean difference −0.09, </offsets><italic><offsets xml_i="38967" xml_f="38968" txt_i="23737" txt_f="23738">p</offsets></italic><offsets xml_i="38977" xml_f="39269" txt_i="23738" txt_f="24030"> = 0.1 vs placebo) at week 100 in the 225-mg dose group. There was no effect on brain amyloid load in either the gantenerumab 105-mg dose group (0.72% change from baseline, absolute mean difference 0.00) or the placebo group (1.09% change from baseline, absolute mean difference −0.02) (Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="39301" xml_f="39302" txt_i="24030" txt_f="24031">3</offsets></xref><offsets xml_i="39309" xml_f="39463" txt_i="24031" txt_f="24185">). Exploratory analyses using alternative reference regions support that the drug-placebo difference at the 225-mg dose level was robust (data not shown).</offsets><fig id="Fig3"><label><offsets xml_i="39485" xml_f="39491" txt_i="24185" txt_f="24191">Fig. 3</offsets></label><caption><p><offsets xml_i="39511" xml_f="39567" txt_i="24191" txt_f="24247">Mean (±SE) change from baseline in PET SUVr (cerebellar </offsets><italic><offsets xml_i="39575" xml_f="39579" txt_i="24247" txt_f="24251">gray</offsets></italic><offsets xml_i="39588" xml_f="39602" txt_i="24251" txt_f="24265"> reference). *</offsets><italic><offsets xml_i="39610" xml_f="39611" txt_i="24265" txt_f="24266">p</offsets></italic><offsets xml_i="39620" xml_f="39643" txt_i="24266" txt_f="24286"> &lt; 0.01 vs placebo. </offsets><italic><offsets xml_i="39651" xml_f="39659" txt_i="24286" txt_f="24294">PET SUVr</offsets></italic><offsets xml_i="39668" xml_f="39729" txt_i="24294" txt_f="24355"> Positron emission tomography standardized uptake value ratio</offsets></p></caption><graphic xlink:href="13195_2017_318_Fig3_HTML" id="MO3"></graphic></fig><offsets xml_i="39815" xml_f="39816" txt_i="24356" txt_f="24357">
</offsets></p></sec><sec id="Sec21"><title><offsets xml_i="39849" xml_f="39862" txt_i="24359" txt_f="24372">MRI volumetry</offsets></title><p id="Par63"><offsets xml_i="39884" xml_f="40082" txt_i="24373" txt_f="24571">No difference between treatment arms at either of the doses tested was seen for any volumetric MRI measure investigated: whole brain, left/right hippocampal, and ventricular volume (data not shown).</offsets></p></sec><sec id="Sec22"><title><offsets xml_i="40115" xml_f="40118" txt_i="24573" txt_f="24576">CSF</offsets></title><p id="Par64"><offsets xml_i="40140" xml_f="40312" txt_i="24577" txt_f="24749">CSF samples were not collected from all individuals postbaseline. Statistical analysis was performed on samples from patients who had at least one postbaseline CSF sample (</offsets><italic><offsets xml_i="40320" xml_f="40321" txt_i="24749" txt_f="24750">n</offsets></italic><offsets xml_i="40330" xml_f="40542" txt_i="24750" txt_f="24962"> = 209). For neurogranin, the numbers were lower because of assay performance; that is, data from patients with neurogranin levels below the limit of quantification were excluded. Results are summarized in Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="40576" xml_f="40577" txt_i="24962" txt_f="24963">3</offsets></xref><offsets xml_i="40584" xml_f="40665" txt_i="24963" txt_f="25044">. Results suggested dose- and time-dependent reductions in t-tau and p-tau (Fig. </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="40697" xml_f="40698" txt_i="25044" txt_f="25045">4</offsets></xref><offsets xml_i="40705" xml_f="40880" txt_i="25045" txt_f="25220">). At week 104, significantly greater reductions from baseline in the gantenerumab 105 mg and 225 mg treatment arms compared with the placebo arm were observed for CSF p-tau (</offsets><italic><offsets xml_i="40888" xml_f="40889" txt_i="25220" txt_f="25221">p</offsets></italic><offsets xml_i="40898" xml_f="40911" txt_i="25221" txt_f="25234"> ≤ 0.001 and </offsets><italic><offsets xml_i="40919" xml_f="40920" txt_i="25234" txt_f="25235">p</offsets></italic><offsets xml_i="40929" xml_f="40964" txt_i="25235" txt_f="25270"> ≤ 0.001, respectively) and t-tau (</offsets><italic><offsets xml_i="40972" xml_f="40973" txt_i="25270" txt_f="25271">p</offsets></italic><offsets xml_i="40982" xml_f="40994" txt_i="25271" txt_f="25283"> = 0.05 and </offsets><italic><offsets xml_i="41002" xml_f="41003" txt_i="25283" txt_f="25284">p</offsets></italic><offsets xml_i="41012" xml_f="41120" txt_i="25284" txt_f="25392"> = 0.02, respectively). The results also suggested a reduction of CSF neurogranin at the higher dose (Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="41154" xml_f="41155" txt_i="25392" txt_f="25393">3</offsets></xref><offsets xml_i="41162" xml_f="41169" txt_i="25393" txt_f="25400">, Fig. </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="41201" xml_f="41202" txt_i="25400" txt_f="25401">4</offsets></xref><offsets xml_i="41209" xml_f="41257" txt_i="25401" txt_f="25449">). No significant change in the levels of CSF Aβ</offsets><sub><offsets xml_i="41262" xml_f="41264" txt_i="25449" txt_f="25451">42</offsets></sub><offsets xml_i="41270" xml_f="41431" txt_i="25451" txt_f="25612"> over 2 years of gantenerumab treatment compared with placebo were observed, even though a numerical increase was seen with gantenerumab 225 mg at week 104 only.</offsets><table-wrap id="Tab3"><label><offsets xml_i="41460" xml_f="41467" txt_i="25612" txt_f="25619">Table 3</offsets></label><caption><p><offsets xml_i="41487" xml_f="41525" txt_i="25619" txt_f="25657">Cerebrospinal fluid biomarker findings</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><offsets xml_i="41603" xml_f="41635" txt_i="25658" txt_f="25690">Change from baseline at week 104</offsets></th><th><offsets xml_i="41644" xml_f="41651" txt_i="25690" txt_f="25697">Placebo</offsets></th><th colspan="2"><offsets xml_i="41672" xml_f="41691" txt_i="25697" txt_f="25716">Gantenerumab 105 mg</offsets></th><th colspan="2"><offsets xml_i="41712" xml_f="41731" txt_i="25716" txt_f="25735">Gantenerumab 225 mg</offsets></th></tr><tr><th><offsets xml_i="41749" xml_f="41776" txt_i="25735" txt_f="25762">Change (%), median (Q1, Q3)</offsets></th><th><offsets xml_i="41785" xml_f="41812" txt_i="25762" txt_f="25789">Change (%), median (Q1, Q3)</offsets></th><th><offsets xml_i="41821" xml_f="41822" txt_i="25789" txt_f="25790">
</offsets><italic><offsets xml_i="41830" xml_f="41831" txt_i="25790" txt_f="25791">p</offsets></italic><offsets xml_i="41840" xml_f="41857" txt_i="25791" txt_f="25808"> Value vs placebo</offsets></th><th><offsets xml_i="41866" xml_f="41893" txt_i="25808" txt_f="25835">Change (%), median (Q1, Q3)</offsets></th><th><offsets xml_i="41902" xml_f="41903" txt_i="25835" txt_f="25836">
</offsets><italic><offsets xml_i="41911" xml_f="41912" txt_i="25836" txt_f="25837">p</offsets></italic><offsets xml_i="41921" xml_f="41938" txt_i="25837" txt_f="25854"> Value vs placebo</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="41971" xml_f="41973" txt_i="25854" txt_f="25856">Aβ</offsets><sub><offsets xml_i="41978" xml_f="41980" txt_i="25856" txt_f="25858">42</offsets></sub><offsets xml_i="41986" xml_f="41993" txt_i="25858" txt_f="25865">, pg/ml</offsets></td><td><offsets xml_i="42002" xml_f="42003" txt_i="25866" txt_f="25867">
</offsets><italic><offsets xml_i="42011" xml_f="42012" txt_i="25867" txt_f="25868">n</offsets></italic><offsets xml_i="42021" xml_f="42026" txt_i="25868" txt_f="25873"> = 72</offsets><break></break><offsets xml_i="42041" xml_f="42047" txt_i="25873" txt_f="25879">−0.85%</offsets><break></break><offsets xml_i="42062" xml_f="42077" txt_i="25879" txt_f="25894">(−15.31, 21.03)</offsets></td><td><offsets xml_i="42086" xml_f="42087" txt_i="25895" txt_f="25896">
</offsets><italic><offsets xml_i="42095" xml_f="42096" txt_i="25896" txt_f="25897">n</offsets></italic><offsets xml_i="42105" xml_f="42110" txt_i="25897" txt_f="25902"> = 71</offsets><break></break><offsets xml_i="42125" xml_f="42131" txt_i="25902" txt_f="25908">−1.06%</offsets><break></break><offsets xml_i="42146" xml_f="42161" txt_i="25908" txt_f="25923">(−19.33, 25.88)</offsets></td><td><offsets xml_i="42170" xml_f="42174" txt_i="25924" txt_f="25928">0.98</offsets></td><td><offsets xml_i="42183" xml_f="42184" txt_i="25929" txt_f="25930">
</offsets><italic><offsets xml_i="42192" xml_f="42193" txt_i="25930" txt_f="25931">n</offsets></italic><offsets xml_i="42202" xml_f="42207" txt_i="25931" txt_f="25936"> = 66</offsets><break></break><offsets xml_i="42222" xml_f="42227" txt_i="25936" txt_f="25941">7.55%</offsets><break></break><offsets xml_i="42242" xml_f="42257" txt_i="25941" txt_f="25956">(−13.96, 35.09)</offsets></td><td><offsets xml_i="42266" xml_f="42270" txt_i="25957" txt_f="25961">0.09</offsets></td></tr><tr><td><offsets xml_i="42288" xml_f="42300" txt_i="25962" txt_f="25974">t-tau, pg/ml</offsets></td><td><offsets xml_i="42309" xml_f="42310" txt_i="25975" txt_f="25976">
</offsets><italic><offsets xml_i="42318" xml_f="42319" txt_i="25976" txt_f="25977">n</offsets></italic><offsets xml_i="42328" xml_f="42333" txt_i="25977" txt_f="25982"> = 72</offsets><break></break><offsets xml_i="42348" xml_f="42353" txt_i="25982" txt_f="25987">2.04%</offsets><break></break><offsets xml_i="42368" xml_f="42381" txt_i="25987" txt_f="26000">(−4.56, 8.72)</offsets></td><td><offsets xml_i="42390" xml_f="42391" txt_i="26001" txt_f="26002">
</offsets><italic><offsets xml_i="42399" xml_f="42400" txt_i="26002" txt_f="26003">n</offsets></italic><offsets xml_i="42409" xml_f="42414" txt_i="26003" txt_f="26008"> = 71</offsets><break></break><offsets xml_i="42429" xml_f="42435" txt_i="26008" txt_f="26014">−1.08%</offsets><break></break><offsets xml_i="42450" xml_f="42463" txt_i="26014" txt_f="26027">(−7.65, 5.86)</offsets></td><td><offsets xml_i="42472" xml_f="42476" txt_i="26028" txt_f="26032">0.05</offsets></td><td><offsets xml_i="42485" xml_f="42486" txt_i="26033" txt_f="26034">
</offsets><italic><offsets xml_i="42494" xml_f="42495" txt_i="26034" txt_f="26035">n</offsets></italic><offsets xml_i="42504" xml_f="42509" txt_i="26035" txt_f="26040"> = 66</offsets><break></break><offsets xml_i="42524" xml_f="42530" txt_i="26040" txt_f="26046">−2.91%</offsets><break></break><offsets xml_i="42545" xml_f="42558" txt_i="26046" txt_f="26059">(−8.54, 3.40)</offsets></td><td><offsets xml_i="42567" xml_f="42571" txt_i="26060" txt_f="26064">0.02</offsets></td></tr><tr><td><offsets xml_i="42589" xml_f="42601" txt_i="26065" txt_f="26077">p-tau, pg/ml</offsets></td><td><offsets xml_i="42610" xml_f="42611" txt_i="26078" txt_f="26079">
</offsets><italic><offsets xml_i="42619" xml_f="42620" txt_i="26079" txt_f="26080">n</offsets></italic><offsets xml_i="42629" xml_f="42634" txt_i="26080" txt_f="26085"> = 72</offsets><break></break><offsets xml_i="42649" xml_f="42654" txt_i="26085" txt_f="26090">0.08%</offsets><break></break><offsets xml_i="42669" xml_f="42682" txt_i="26090" txt_f="26103">(−3.91, 6.49)</offsets></td><td><offsets xml_i="42691" xml_f="42692" txt_i="26104" txt_f="26105">
</offsets><italic><offsets xml_i="42700" xml_f="42701" txt_i="26105" txt_f="26106">n</offsets></italic><offsets xml_i="42710" xml_f="42715" txt_i="26106" txt_f="26111"> = 71</offsets><break></break><offsets xml_i="42730" xml_f="42736" txt_i="26111" txt_f="26117">−5.61%</offsets><break></break><offsets xml_i="42751" xml_f="42765" txt_i="26117" txt_f="26131">(−11.07, 0.97)</offsets></td><td><offsets xml_i="42774" xml_f="42781" txt_i="26132" txt_f="26139">≤ 0.001</offsets></td><td><offsets xml_i="42790" xml_f="42791" txt_i="26140" txt_f="26141">
</offsets><italic><offsets xml_i="42799" xml_f="42800" txt_i="26141" txt_f="26142">n</offsets></italic><offsets xml_i="42809" xml_f="42814" txt_i="26142" txt_f="26147"> = 66</offsets><break></break><offsets xml_i="42829" xml_f="42835" txt_i="26147" txt_f="26153">−7.15%</offsets><break></break><offsets xml_i="42850" xml_f="42865" txt_i="26153" txt_f="26168">(−14.48, −2.41)</offsets></td><td><offsets xml_i="42874" xml_f="42881" txt_i="26169" txt_f="26176">≤ 0.001</offsets></td></tr><tr><td><offsets xml_i="42899" xml_f="42917" txt_i="26177" txt_f="26195">Neurogranin, pg/ml</offsets></td><td><offsets xml_i="42926" xml_f="42927" txt_i="26196" txt_f="26197">
</offsets><italic><offsets xml_i="42935" xml_f="42936" txt_i="26197" txt_f="26198">n</offsets></italic><offsets xml_i="42945" xml_f="42950" txt_i="26198" txt_f="26203"> = 65</offsets><break></break><offsets xml_i="42965" xml_f="42971" txt_i="26203" txt_f="26209">−3.24%</offsets><break></break><offsets xml_i="42986" xml_f="43001" txt_i="26209" txt_f="26224">(−20.64, 12.27)</offsets></td><td><offsets xml_i="43010" xml_f="43011" txt_i="26225" txt_f="26226">
</offsets><italic><offsets xml_i="43019" xml_f="43020" txt_i="26226" txt_f="26227">n</offsets></italic><offsets xml_i="43029" xml_f="43034" txt_i="26227" txt_f="26232"> = 66</offsets><break></break><offsets xml_i="43049" xml_f="43055" txt_i="26232" txt_f="26238">−4.58%</offsets><break></break><offsets xml_i="43070" xml_f="43085" txt_i="26238" txt_f="26253">(−19.89, 10.13)</offsets></td><td><offsets xml_i="43094" xml_f="43098" txt_i="26254" txt_f="26258">0.79</offsets></td><td><offsets xml_i="43107" xml_f="43108" txt_i="26259" txt_f="26260">
</offsets><italic><offsets xml_i="43116" xml_f="43117" txt_i="26260" txt_f="26261">n</offsets></italic><offsets xml_i="43126" xml_f="43131" txt_i="26261" txt_f="26266"> = 63</offsets><break></break><offsets xml_i="43146" xml_f="43153" txt_i="26266" txt_f="26273">−11.76%</offsets><break></break><offsets xml_i="43168" xml_f="43182" txt_i="26273" txt_f="26287">(−23.69, 6.48)</offsets></td><td><offsets xml_i="43191" xml_f="43195" txt_i="26288" txt_f="26292">0.18</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="43241" xml_f="43242" txt_i="26293" txt_f="26294">
</offsets><italic><offsets xml_i="43250" xml_f="43267" txt_i="26294" txt_f="26311">Abbreviations: Aβ</offsets></italic><offsets xml_i="43276" xml_f="43291" txt_i="26311" txt_f="26326"> Amyloid-beta, </offsets><italic><offsets xml_i="43299" xml_f="43304" txt_i="26326" txt_f="26331">p-tau</offsets></italic><offsets xml_i="43313" xml_f="43334" txt_i="26331" txt_f="26352"> Phosphorylated tau, </offsets><italic><offsets xml_i="43342" xml_f="43347" txt_i="26352" txt_f="26357">t-tau</offsets></italic><offsets xml_i="43356" xml_f="43366" txt_i="26357" txt_f="26367"> Total tau</offsets></p></table-wrap-foot></table-wrap><offsets xml_i="43401" xml_f="43402" txt_i="26368" txt_f="26369">
</offsets><fig id="Fig4"><label><offsets xml_i="43424" xml_f="43430" txt_i="26369" txt_f="26375">Fig. 4</offsets></label><caption><p><offsets xml_i="43450" xml_f="43522" txt_i="26375" txt_f="26447">Percentage changes in median cerebrospinal fluid biomarker levels for Aβ</offsets><sub><offsets xml_i="43527" xml_f="43531" txt_i="26447" txt_f="26451">1–42</offsets></sub><offsets xml_i="43537" xml_f="43571" txt_i="26451" txt_f="26485">, p-tau, t-tau, and neurogranin. *</offsets><italic><offsets xml_i="43579" xml_f="43580" txt_i="26485" txt_f="26486">p</offsets></italic><offsets xml_i="43589" xml_f="43600" txt_i="26486" txt_f="26497"> ≤ 0.05; **</offsets><italic><offsets xml_i="43608" xml_f="43609" txt_i="26497" txt_f="26498">p</offsets></italic><offsets xml_i="43618" xml_f="43631" txt_i="26498" txt_f="26511"> ≤ 0.005; ***</offsets><italic><offsets xml_i="43639" xml_f="43640" txt_i="26511" txt_f="26512">p</offsets></italic><offsets xml_i="43649" xml_f="43660" txt_i="26512" txt_f="26523"> ≤ 0.0001. </offsets><italic><offsets xml_i="43668" xml_f="43670" txt_i="26523" txt_f="26525">Aβ</offsets></italic><offsets xml_i="43679" xml_f="43694" txt_i="26525" txt_f="26540"> Amyloid-beta, </offsets><italic><offsets xml_i="43702" xml_f="43707" txt_i="26540" txt_f="26545">p-tau</offsets></italic><offsets xml_i="43716" xml_f="43739" txt_i="26545" txt_f="26568"> Phosphorylated tau 181</offsets></p></caption><graphic xlink:href="13195_2017_318_Fig4_HTML" id="MO4"></graphic></fig><offsets xml_i="43825" xml_f="43826" txt_i="26569" txt_f="26570">
</offsets></p></sec></sec><sec id="Sec23"><title><offsets xml_i="43865" xml_f="43893" txt_i="26573" txt_f="26601">Further exploratory analyses</offsets></title><p id="Par65"><offsets xml_i="43915" xml_f="44397" txt_i="26602" txt_f="27084">Despite the results of the futility analysis, the presence of a drug effect on biomarkers of target engagement and neurodegeneration, as described above, triggered further exploratory analyses to gain understanding of the results of the study and to potentially guide future development of gantenerumab. An aspect of this analysis was to explore the impact of the observed rate of disease progression in the prodromal AD population. These analyses were limited to 2-year completers.</offsets></p><p id="Par66"><offsets xml_i="44415" xml_f="44582" txt_i="27085" txt_f="27252">Before the SCarlet RoAD study was unblinded, an AD progression model was built for CDR-SB score using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (</offsets><ext-link ext-link-type="uri" xlink:href="http://adni.loni.usc.edu/"><offsets xml_i="44651" xml_f="44676" txt_i="27252" txt_f="27277">http://adni.loni.usc.edu/</offsets></ext-link><offsets xml_i="44687" xml_f="44690" txt_i="27277" txt_f="27280">) [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="44723" xml_f="44725" txt_i="27280" txt_f="27282">20</offsets></xref><offsets xml_i="44732" xml_f="45168" txt_i="27282" txt_f="27718">]. The model distinguishes two population types: “slow” progressing and “fast” progressing. Further statistical investigations over a large series of potential covariates at baseline determined CDR-SB, FAQ, and hippocampal volume to be the three main factors in predicting progression type and a prognostic “signature” was therefore proposed as a method to predict “fast” or “slow” progression of disease for patients with prodromal AD.</offsets></p><p id="Par67"><offsets xml_i="45186" xml_f="45356" txt_i="27719" txt_f="27889">Applying this algorithm to the SCarlet RoAD 2-year completer population (baseline data), almost two-thirds of the trial population were predicted to be slow progressors (</offsets><italic><offsets xml_i="45364" xml_f="45365" txt_i="27889" txt_f="27890">n</offsets></italic><offsets xml_i="45374" xml_f="45438" txt_i="27890" txt_f="27954"> = 202), and one-third could be designated as fast progressors (</offsets><italic><offsets xml_i="45446" xml_f="45447" txt_i="27954" txt_f="27955">n</offsets></italic><offsets xml_i="45456" xml_f="45471" txt_i="27955" txt_f="27970"> = 108) (Table </offsets><xref rid="Tab4" ref-type="table"><offsets xml_i="45505" xml_f="45506" txt_i="27970" txt_f="27971">4</offsets></xref><offsets xml_i="45513" xml_f="45737" txt_i="27971" txt_f="28195">). By design, fast and slow progressors have slightly different mean baseline characteristics, with fast progressors having higher baseline FAQ and CDR-SB and smaller hippocampal volume. Fast progressors also included fewer </offsets><italic><offsets xml_i="45745" xml_f="45749" txt_i="28195" txt_f="28199">APOE</offsets></italic><offsets xml_i="45758" xml_f="46082" txt_i="28199" txt_f="28523"> ε4 noncarriers. However, within the fast and slow subgroups, baseline characteristics appeared well balanced between the treatment arms (data not shown). Given the small sample size in the subgroups of this exploratory analysis, it was deemed that median and IQR data would be adequate summary statistics to report results.</offsets><table-wrap id="Tab4"><label><offsets xml_i="46111" xml_f="46118" txt_i="28523" txt_f="28530">Table 4</offsets></label><caption><p><offsets xml_i="46138" xml_f="46194" txt_i="28530" txt_f="28586">Fast and slow progressors in the SCarlet RoAD population</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><offsets xml_i="46272" xml_f="46303" txt_i="28587" txt_f="28618">Variable, median score (Q1; Q3)</offsets></th><th colspan="6"><offsets xml_i="46324" xml_f="46358" txt_i="28618" txt_f="28652">Change from baseline at week 104 (</offsets><italic><offsets xml_i="46366" xml_f="46367" txt_i="28652" txt_f="28653">n</offsets></italic><offsets xml_i="46376" xml_f="46382" txt_i="28653" txt_f="28659"> = 310</offsets><sup><offsets xml_i="46387" xml_f="46388" txt_i="28659" txt_f="28660">a</offsets></sup><offsets xml_i="46394" xml_f="46395" txt_i="28660" txt_f="28661">)</offsets></th></tr><tr><th colspan="3"><offsets xml_i="46425" xml_f="46443" txt_i="28661" txt_f="28679">Slow progressors (</offsets><italic><offsets xml_i="46451" xml_f="46452" txt_i="28679" txt_f="28680">n</offsets></italic><offsets xml_i="46461" xml_f="46468" txt_i="28680" txt_f="28687"> = 202)</offsets></th><th colspan="3"><offsets xml_i="46489" xml_f="46507" txt_i="28687" txt_f="28705">Fast progressors (</offsets><italic><offsets xml_i="46515" xml_f="46516" txt_i="28705" txt_f="28706">n</offsets></italic><offsets xml_i="46525" xml_f="46532" txt_i="28706" txt_f="28713"> = 108)</offsets></th></tr><tr><th></th><th><offsets xml_i="46559" xml_f="46568" txt_i="28713" txt_f="28722">Placebo (</offsets><italic><offsets xml_i="46576" xml_f="46577" txt_i="28722" txt_f="28723">n</offsets></italic><offsets xml_i="46586" xml_f="46592" txt_i="28723" txt_f="28729"> = 70)</offsets></th><th><offsets xml_i="46601" xml_f="46613" txt_i="28729" txt_f="28741">Gantenerumab</offsets><break></break><offsets xml_i="46628" xml_f="46634" txt_i="28741" txt_f="28747">105 mg</offsets><break></break><offsets xml_i="46649" xml_f="46650" txt_i="28747" txt_f="28748">(</offsets><italic><offsets xml_i="46658" xml_f="46659" txt_i="28748" txt_f="28749">n</offsets></italic><offsets xml_i="46668" xml_f="46674" txt_i="28749" txt_f="28755"> = 57)</offsets></th><th><offsets xml_i="46683" xml_f="46695" txt_i="28755" txt_f="28767">Gantenerumab</offsets><break></break><offsets xml_i="46710" xml_f="46716" txt_i="28767" txt_f="28773">225 mg</offsets><break></break><offsets xml_i="46731" xml_f="46732" txt_i="28773" txt_f="28774">(</offsets><italic><offsets xml_i="46740" xml_f="46741" txt_i="28774" txt_f="28775">n</offsets></italic><offsets xml_i="46750" xml_f="46756" txt_i="28775" txt_f="28781"> = 75)</offsets></th><th><offsets xml_i="46765" xml_f="46774" txt_i="28781" txt_f="28790">Placebo (</offsets><italic><offsets xml_i="46782" xml_f="46783" txt_i="28790" txt_f="28791">n</offsets></italic><offsets xml_i="46792" xml_f="46798" txt_i="28791" txt_f="28797"> = 35)</offsets></th><th><offsets xml_i="46807" xml_f="46819" txt_i="28797" txt_f="28809">Gantenerumab</offsets><break></break><offsets xml_i="46834" xml_f="46840" txt_i="28809" txt_f="28815">105 mg</offsets><break></break><offsets xml_i="46855" xml_f="46856" txt_i="28815" txt_f="28816">(</offsets><italic><offsets xml_i="46864" xml_f="46865" txt_i="28816" txt_f="28817">n</offsets></italic><offsets xml_i="46874" xml_f="46880" txt_i="28817" txt_f="28823"> = 47)</offsets></th><th><offsets xml_i="46889" xml_f="46901" txt_i="28823" txt_f="28835">Gantenerumab</offsets><break></break><offsets xml_i="46916" xml_f="46922" txt_i="28835" txt_f="28841">225 mg</offsets><break></break><offsets xml_i="46937" xml_f="46938" txt_i="28841" txt_f="28842">(</offsets><italic><offsets xml_i="46946" xml_f="46947" txt_i="28842" txt_f="28843">n</offsets></italic><offsets xml_i="46956" xml_f="46962" txt_i="28843" txt_f="28849"> = 26)</offsets></th></tr></thead><tbody><tr><td colspan="7"><offsets xml_i="47007" xml_f="47023" txt_i="28849" txt_f="28865">Primary endpoint</offsets></td></tr><tr><td><offsets xml_i="47041" xml_f="47048" txt_i="28866" txt_f="28873"> CDR-SB</offsets></td><td><offsets xml_i="47057" xml_f="47069" txt_i="28874" txt_f="28886">0.5 (0, 1.5)</offsets></td><td><offsets xml_i="47078" xml_f="47088" txt_i="28887" txt_f="28897">0.5 (0, 2)</offsets></td><td><offsets xml_i="47097" xml_f="47109" txt_i="28898" txt_f="28910">1.0 (0, 1.5)</offsets></td><td><offsets xml_i="47118" xml_f="47130" txt_i="28911" txt_f="28923">1.5 (0.5, 3)</offsets></td><td><offsets xml_i="47139" xml_f="47152" txt_i="28924" txt_f="28937">1.0 (0, 2.75)</offsets></td><td><offsets xml_i="47161" xml_f="47174" txt_i="28938" txt_f="28951">2.0 (1, 2.88)</offsets></td></tr><tr><td colspan="7"><offsets xml_i="47204" xml_f="47223" txt_i="28952" txt_f="28971">Secondary endpoints</offsets></td></tr><tr><td><offsets xml_i="47241" xml_f="47253" txt_i="28972" txt_f="28984"> ADAS-Cog 13</offsets></td><td><offsets xml_i="47262" xml_f="47280" txt_i="28985" txt_f="29003">3.34 (−1.41, 8.41)</offsets></td><td><offsets xml_i="47289" xml_f="47305" txt_i="29004" txt_f="29020">3.5 (−2.5, 6.25)</offsets></td><td><offsets xml_i="47314" xml_f="47332" txt_i="29021" txt_f="29039">3.33 (−0.34, 8.67)</offsets></td><td><offsets xml_i="47341" xml_f="47358" txt_i="29040" txt_f="29057">6.0 (2.34, 12.17)</offsets></td><td><offsets xml_i="47367" xml_f="47383" txt_i="29058" txt_f="29074">4.84 (1.5, 7.92)</offsets></td><td><offsets xml_i="47392" xml_f="47408" txt_i="29075" txt_f="29091">2.66 (0.67, 7.5)</offsets></td></tr><tr><td><offsets xml_i="47426" xml_f="47433" txt_i="29092" txt_f="29099"> CANTAB</offsets></td><td><offsets xml_i="47442" xml_f="47462" txt_i="29100" txt_f="29120">−1.43 (−2.52, −0.31)</offsets></td><td><offsets xml_i="47471" xml_f="47487" txt_i="29121" txt_f="29137">−1.14 (−3, 0.97)</offsets></td><td><offsets xml_i="47496" xml_f="47515" txt_i="29138" txt_f="29157">−0.99 (−3.22, 0.56)</offsets></td><td><offsets xml_i="47524" xml_f="47543" txt_i="29158" txt_f="29177">−2.42 (−4.09, 0.07)</offsets></td><td><offsets xml_i="47552" xml_f="47571" txt_i="29178" txt_f="29197">−1.31 (−3.27, 0.25)</offsets></td><td><offsets xml_i="47580" xml_f="47599" txt_i="29198" txt_f="29217">−0.81 (−1.98, 0.69)</offsets></td></tr><tr><td><offsets xml_i="47617" xml_f="47621" txt_i="29218" txt_f="29222"> FAQ</offsets></td><td><offsets xml_i="47630" xml_f="47638" txt_i="29223" txt_f="29231">1 (0, 5)</offsets></td><td><offsets xml_i="47647" xml_f="47655" txt_i="29232" txt_f="29240">1 (0, 7)</offsets></td><td><offsets xml_i="47664" xml_f="47672" txt_i="29241" txt_f="29249">2 (0, 6)</offsets></td><td><offsets xml_i="47681" xml_f="47691" txt_i="29250" txt_f="29260">5 (2.5, 8)</offsets></td><td><offsets xml_i="47700" xml_f="47710" txt_i="29261" txt_f="29271">6 (2, 8.5)</offsets></td><td><offsets xml_i="47719" xml_f="47727" txt_i="29272" txt_f="29280">4 (1, 9)</offsets></td></tr><tr><td><offsets xml_i="47745" xml_f="47750" txt_i="29281" txt_f="29286"> MMSE</offsets></td><td><offsets xml_i="47759" xml_f="47769" txt_i="29287" txt_f="29297">−1 (−4, 0)</offsets></td><td><offsets xml_i="47778" xml_f="47791" txt_i="29298" txt_f="29311">−1 (−4, 0.25)</offsets></td><td><offsets xml_i="47800" xml_f="47810" txt_i="29312" txt_f="29322">−2 (−3, 0)</offsets></td><td><offsets xml_i="47819" xml_f="47835" txt_i="29323" txt_f="29339">−3.5 (−4.75, −2)</offsets></td><td><offsets xml_i="47844" xml_f="47856" txt_i="29340" txt_f="29352">−3 (−4.5, 0)</offsets></td><td><offsets xml_i="47865" xml_f="47875" txt_i="29353" txt_f="29363">−2 (−4, 0)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="47921" xml_f="47922" txt_i="29364" txt_f="29365">
</offsets><italic><offsets xml_i="47930" xml_f="47956" txt_i="29365" txt_f="29391">Abbreviations: ADAS-Cog 13</offsets></italic><offsets xml_i="47965" xml_f="48023" txt_i="29391" txt_f="29449"> Alzheimer’s Disease Assessment Scale–Cognitive subscale, </offsets><italic><offsets xml_i="48031" xml_f="48037" txt_i="29449" txt_f="29455">CANTAB</offsets></italic><offsets xml_i="48046" xml_f="48100" txt_i="29455" txt_f="29509"> Cambridge Neuropsychological Test Automated Battery, </offsets><italic><offsets xml_i="48108" xml_f="48114" txt_i="29509" txt_f="29515">CDR-SB</offsets></italic><offsets xml_i="48123" xml_f="48163" txt_i="29515" txt_f="29555"> Clinical Dementia Rating Sum of Boxes, </offsets><italic><offsets xml_i="48171" xml_f="48174" txt_i="29555" txt_f="29558">FAQ</offsets></italic><offsets xml_i="48183" xml_f="48221" txt_i="29558" txt_f="29596"> Functional Activities Questionnaire, </offsets><italic><offsets xml_i="48229" xml_f="48233" txt_i="29596" txt_f="29600">MMSE</offsets></italic><offsets xml_i="48242" xml_f="48272" txt_i="29600" txt_f="29630"> Mini Mental State Examination</offsets></p><p><offsets xml_i="48279" xml_f="48280" txt_i="29631" txt_f="29632">
</offsets><sup><offsets xml_i="48285" xml_f="48286" txt_i="29632" txt_f="29633">a</offsets></sup><offsets xml_i="48292" xml_f="48402" txt_i="29633" txt_f="29743">Six patients completing study drug treatment had missing efficacy assessment at the week 104 visit time window</offsets></p></table-wrap-foot></table-wrap><offsets xml_i="48437" xml_f="48438" txt_i="29744" txt_f="29745">
</offsets></p><p id="Par68"><offsets xml_i="48456" xml_f="48641" txt_i="29746" txt_f="29931">In the fast progressor subgroup, results suggested a dose-dependent slowing of decline in ADAS-Cog 13, CANTAB, and MMSE, but not in CDR-SB score change, from baseline at 2 years (Table </offsets><xref rid="Tab4" ref-type="table"><offsets xml_i="48675" xml_f="48676" txt_i="29931" txt_f="29932">4</offsets></xref><offsets xml_i="48683" xml_f="48778" txt_i="29932" txt_f="30027">). The slow progressor subgroup did not show any difference in decline across treatment groups.</offsets></p></sec><sec id="Sec24"><title><offsets xml_i="48811" xml_f="48825" txt_i="30029" txt_f="30043">Adverse events</offsets></title><p id="Par69"><offsets xml_i="48847" xml_f="48949" txt_i="30044" txt_f="30146">No notable differences were seen in the rate of serious adverse events and death across groups (Table </offsets><xref rid="Tab5" ref-type="table"><offsets xml_i="48983" xml_f="48984" txt_i="30146" txt_f="30147">5</offsets></xref><offsets xml_i="48991" xml_f="49171" txt_i="30147" txt_f="30324">). Two adverse event terms were reported in gantenerumab-treated patients at a rate of &gt; 5% and twofold greater than in the placebo arm: injection site erythema and ARIA (Table </offsets><xref rid="Tab6" ref-type="table"><offsets xml_i="49205" xml_f="49206" txt_i="30324" txt_f="30325">6</offsets></xref><offsets xml_i="49213" xml_f="49215" txt_i="30325" txt_f="30327">).</offsets><table-wrap id="Tab5"><label><offsets xml_i="49244" xml_f="49251" txt_i="30327" txt_f="30334">Table 5</offsets></label><caption><p><offsets xml_i="49271" xml_f="49296" txt_i="30334" txt_f="30359">Summary of adverse events</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><offsets xml_i="49374" xml_f="49379" txt_i="30360" txt_f="30365">Event</offsets></th><th colspan="3"><offsets xml_i="49400" xml_f="49429" txt_i="30365" txt_f="30394">Safety evaluable population (</offsets><italic><offsets xml_i="49437" xml_f="49438" txt_i="30394" txt_f="30395">n</offsets></italic><offsets xml_i="49447" xml_f="49454" txt_i="30395" txt_f="30402"> = 797)</offsets></th></tr><tr><th><offsets xml_i="49472" xml_f="49479" txt_i="30402" txt_f="30409">Placebo</offsets><break></break><offsets xml_i="49494" xml_f="49495" txt_i="30409" txt_f="30410">(</offsets><italic><offsets xml_i="49503" xml_f="49504" txt_i="30410" txt_f="30411">n</offsets></italic><offsets xml_i="49513" xml_f="49520" txt_i="30411" txt_f="30418"> = 266)</offsets></th><th><offsets xml_i="49529" xml_f="49548" txt_i="30418" txt_f="30437">Gantenerumab 105 mg</offsets><break></break><offsets xml_i="49563" xml_f="49564" txt_i="30437" txt_f="30438">(</offsets><italic><offsets xml_i="49572" xml_f="49573" txt_i="30438" txt_f="30439">n</offsets></italic><offsets xml_i="49582" xml_f="49589" txt_i="30439" txt_f="30446"> = 271)</offsets></th><th><offsets xml_i="49598" xml_f="49617" txt_i="30446" txt_f="30465">Gantenerumab 225 mg</offsets><break></break><offsets xml_i="49632" xml_f="49633" txt_i="30465" txt_f="30466">(</offsets><italic><offsets xml_i="49641" xml_f="49642" txt_i="30466" txt_f="30467">n</offsets></italic><offsets xml_i="49651" xml_f="49658" txt_i="30467" txt_f="30474"> = 260)</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="49691" xml_f="49708" txt_i="30474" txt_f="30491">Any adverse event</offsets></td><td><offsets xml_i="49717" xml_f="49728" txt_i="30492" txt_f="30503">250 (94.0%)</offsets></td><td><offsets xml_i="49737" xml_f="49748" txt_i="30504" txt_f="30515">241 (88.9%)</offsets></td><td><offsets xml_i="49757" xml_f="49768" txt_i="30516" txt_f="30527">240 (92.3%)</offsets></td></tr><tr><td><offsets xml_i="49786" xml_f="49811" txt_i="30528" txt_f="30553">Any serious adverse event</offsets></td><td><offsets xml_i="49820" xml_f="49830" txt_i="30554" txt_f="30564">55 (20.7%)</offsets></td><td><offsets xml_i="49839" xml_f="49849" txt_i="30565" txt_f="30575">48 (17.7%)</offsets></td><td><offsets xml_i="49858" xml_f="49868" txt_i="30576" txt_f="30586">46 (17.7%)</offsets></td></tr><tr><td><offsets xml_i="49886" xml_f="49895" txt_i="30587" txt_f="30596">Any death</offsets></td><td><offsets xml_i="49904" xml_f="49912" txt_i="30597" txt_f="30605">6 (2.3%)</offsets></td><td><offsets xml_i="49921" xml_f="49922" txt_i="30606" txt_f="30607">0</offsets></td><td><offsets xml_i="49931" xml_f="49939" txt_i="30608" txt_f="30616">2 (0.8%)</offsets></td></tr><tr><td><offsets xml_i="49957" xml_f="49974" txt_i="30617" txt_f="30634">Cardiac disorders</offsets></td><td><offsets xml_i="49983" xml_f="49992" txt_i="30635" txt_f="30644">24 (9.0%)</offsets></td><td><offsets xml_i="50001" xml_f="50010" txt_i="30645" txt_f="30654">26 (9.6%)</offsets></td><td><offsets xml_i="50019" xml_f="50028" txt_i="30655" txt_f="30664">22 (8.5%)</offsets></td></tr><tr><td><offsets xml_i="50046" xml_f="50073" txt_i="30665" txt_f="30692">Ear and labyrinth disorders</offsets></td><td><offsets xml_i="50082" xml_f="50091" txt_i="30693" txt_f="30702">11 (4.1%)</offsets></td><td><offsets xml_i="50100" xml_f="50109" txt_i="30703" txt_f="30712">15 (5.5%)</offsets></td><td><offsets xml_i="50118" xml_f="50127" txt_i="30713" txt_f="30722">13 (5.0%)</offsets></td></tr><tr><td><offsets xml_i="50145" xml_f="50158" txt_i="30723" txt_f="30736">Eye disorders</offsets></td><td><offsets xml_i="50167" xml_f="50176" txt_i="30737" txt_f="30746">20 (7.5%)</offsets></td><td><offsets xml_i="50185" xml_f="50194" txt_i="30747" txt_f="30756">16 (5.9%)</offsets></td><td><offsets xml_i="50203" xml_f="50212" txt_i="30757" txt_f="30766">23 (8.8%)</offsets></td></tr><tr><td><offsets xml_i="50230" xml_f="50256" txt_i="30767" txt_f="30793">Gastrointestinal disorders</offsets></td><td><offsets xml_i="50265" xml_f="50275" txt_i="30794" txt_f="30804">65 (24.4%)</offsets></td><td><offsets xml_i="50284" xml_f="50294" txt_i="30805" txt_f="30815">64 (23.6%)</offsets></td><td><offsets xml_i="50303" xml_f="50313" txt_i="30816" txt_f="30826">63 (24.2%)</offsets></td></tr><tr><td><offsets xml_i="50331" xml_f="50340" txt_i="30827" txt_f="30836"> Diarrhea</offsets></td><td><offsets xml_i="50349" xml_f="50358" txt_i="30837" txt_f="30846">14 (5.3%)</offsets></td><td><offsets xml_i="50367" xml_f="50376" txt_i="30847" txt_f="30856">15 (5.5%)</offsets></td><td><offsets xml_i="50385" xml_f="50394" txt_i="30857" txt_f="30866">15 (5.8%)</offsets></td></tr><tr><td><offsets xml_i="50412" xml_f="50464" txt_i="30867" txt_f="30919">General disorders and administration site conditions</offsets></td><td><offsets xml_i="50473" xml_f="50483" txt_i="30920" txt_f="30930">44 (16.5%)</offsets></td><td><offsets xml_i="50492" xml_f="50502" txt_i="30931" txt_f="30941">78 (28.8%)</offsets></td><td><offsets xml_i="50511" xml_f="50521" txt_i="30942" txt_f="30952">90 (34.6%)</offsets></td></tr><tr><td><offsets xml_i="50539" xml_f="50563" txt_i="30953" txt_f="30977"> Injection site erythema</offsets></td><td><offsets xml_i="50572" xml_f="50580" txt_i="30978" txt_f="30986">3 (1.1%)</offsets></td><td><offsets xml_i="50589" xml_f="50599" txt_i="30987" txt_f="30997">29 (10.7%)</offsets></td><td><offsets xml_i="50608" xml_f="50618" txt_i="30998" txt_f="31008">35 (13.5%)</offsets></td></tr><tr><td><offsets xml_i="50636" xml_f="50644" txt_i="31009" txt_f="31017"> Fatigue</offsets></td><td><offsets xml_i="50653" xml_f="50661" txt_i="31018" txt_f="31026">8 (3.0%)</offsets></td><td><offsets xml_i="50670" xml_f="50678" txt_i="31027" txt_f="31035">7 (2.6%)</offsets></td><td><offsets xml_i="50687" xml_f="50696" txt_i="31036" txt_f="31045">15 (5.8%)</offsets></td></tr><tr><td><offsets xml_i="50714" xml_f="50741" txt_i="31046" txt_f="31073">Infections and infestations</offsets></td><td><offsets xml_i="50750" xml_f="50761" txt_i="31074" txt_f="31085">110 (41.4%)</offsets></td><td><offsets xml_i="50770" xml_f="50781" txt_i="31086" txt_f="31097">110 (40.6%)</offsets></td><td><offsets xml_i="50790" xml_f="50801" txt_i="31098" txt_f="31109">119 (45.8%)</offsets></td></tr><tr><td><offsets xml_i="50819" xml_f="50834" txt_i="31110" txt_f="31125">Nasopharyngitis</offsets></td><td><offsets xml_i="50843" xml_f="50852" txt_i="31126" txt_f="31135">17 (6.4%)</offsets></td><td><offsets xml_i="50861" xml_f="50871" txt_i="31136" txt_f="31146">30 (11.1%)</offsets></td><td><offsets xml_i="50880" xml_f="50889" txt_i="31147" txt_f="31156">20 (7.7%)</offsets></td></tr><tr><td><offsets xml_i="50907" xml_f="50931" txt_i="31157" txt_f="31181"> Urinary tract infection</offsets></td><td><offsets xml_i="50940" xml_f="50949" txt_i="31182" txt_f="31191">26 (9.8%)</offsets></td><td><offsets xml_i="50958" xml_f="50967" txt_i="31192" txt_f="31201">16 (5.9%)</offsets></td><td><offsets xml_i="50976" xml_f="50985" txt_i="31202" txt_f="31211">22 (8.5%)</offsets></td></tr><tr><td><offsets xml_i="51003" xml_f="51037" txt_i="31212" txt_f="31246"> Upper respiratory tract infection</offsets></td><td><offsets xml_i="51046" xml_f="51055" txt_i="31247" txt_f="31256">11 (4.1%)</offsets></td><td><offsets xml_i="51064" xml_f="51073" txt_i="31257" txt_f="31266">13 (4.8%)</offsets></td><td><offsets xml_i="51082" xml_f="51091" txt_i="31267" txt_f="31276">18 (6.9%)</offsets></td></tr><tr><td><offsets xml_i="51109" xml_f="51119" txt_i="31277" txt_f="31287"> Influenza</offsets></td><td><offsets xml_i="51128" xml_f="51137" txt_i="31288" txt_f="31297">13 (4.9%)</offsets></td><td><offsets xml_i="51146" xml_f="51155" txt_i="31298" txt_f="31307">13 (4.8%)</offsets></td><td><offsets xml_i="51164" xml_f="51173" txt_i="31308" txt_f="31317">15 (5.8%)</offsets></td></tr><tr><td><offsets xml_i="51191" xml_f="51202" txt_i="31318" txt_f="31329"> Bronchitis</offsets></td><td><offsets xml_i="51211" xml_f="51220" txt_i="31330" txt_f="31339">10 (3.8%)</offsets></td><td><offsets xml_i="51229" xml_f="51238" txt_i="31340" txt_f="31349">10 (3.7%)</offsets></td><td><offsets xml_i="51247" xml_f="51256" txt_i="31350" txt_f="31359">14 (5.4%)</offsets></td></tr><tr><td><offsets xml_i="51274" xml_f="51321" txt_i="31360" txt_f="31407">Injury, poisoning, and procedural complications</offsets></td><td><offsets xml_i="51330" xml_f="51340" txt_i="31408" txt_f="31418">73 (27.4%)</offsets></td><td><offsets xml_i="51349" xml_f="51359" txt_i="31419" txt_f="31429">65 (24.0%)</offsets></td><td><offsets xml_i="51368" xml_f="51378" txt_i="31430" txt_f="31440">59 (22.7%)</offsets></td></tr><tr><td><offsets xml_i="51396" xml_f="51401" txt_i="31441" txt_f="31446"> Fall</offsets></td><td><offsets xml_i="51410" xml_f="51420" txt_i="31447" txt_f="31457">28 (10.5%)</offsets></td><td><offsets xml_i="51429" xml_f="51438" txt_i="31458" txt_f="31467">23 (8.5%)</offsets></td><td><offsets xml_i="51447" xml_f="51457" txt_i="31468" txt_f="31478">28 (10.8%)</offsets></td></tr><tr><td><offsets xml_i="51475" xml_f="51489" txt_i="31479" txt_f="31493">Investigations</offsets></td><td><offsets xml_i="51498" xml_f="51508" txt_i="31494" txt_f="31504">40 (15.0%)</offsets></td><td><offsets xml_i="51517" xml_f="51527" txt_i="31505" txt_f="31515">35 (12.9%)</offsets></td><td><offsets xml_i="51536" xml_f="51546" txt_i="31516" txt_f="31526">48 (18.5%)</offsets></td></tr><tr><td><offsets xml_i="51564" xml_f="51598" txt_i="31527" txt_f="31561">Metabolism and nutrition disorders</offsets></td><td><offsets xml_i="51607" xml_f="51616" txt_i="31562" txt_f="31571">23 (8.6%)</offsets></td><td><offsets xml_i="51625" xml_f="51634" txt_i="31572" txt_f="31581">21 (7.7%)</offsets></td><td><offsets xml_i="51643" xml_f="51652" txt_i="31582" txt_f="31591">24 (9.2%)</offsets></td></tr><tr><td><offsets xml_i="51670" xml_f="51717" txt_i="31592" txt_f="31639">Musculoskeletal and connective tissue disorders</offsets></td><td><offsets xml_i="51726" xml_f="51736" txt_i="31640" txt_f="31650">82 (30.8%)</offsets></td><td><offsets xml_i="51745" xml_f="51755" txt_i="31651" txt_f="31661">72 (26.6%)</offsets></td><td><offsets xml_i="51764" xml_f="51774" txt_i="31662" txt_f="31672">72 (27.7%)</offsets></td></tr><tr><td><offsets xml_i="51792" xml_f="51802" txt_i="31673" txt_f="31683"> Back pain</offsets></td><td><offsets xml_i="51811" xml_f="51820" txt_i="31684" txt_f="31693">26 (9.8%)</offsets></td><td><offsets xml_i="51829" xml_f="51838" txt_i="31694" txt_f="31703">16 (5.9%)</offsets></td><td><offsets xml_i="51847" xml_f="51856" txt_i="31704" txt_f="31713">25 (9.6%)</offsets></td></tr><tr><td><offsets xml_i="51874" xml_f="51885" txt_i="31714" txt_f="31725"> Arthralgia</offsets></td><td><offsets xml_i="51894" xml_f="51903" txt_i="31726" txt_f="31735">20 (7.5%)</offsets></td><td><offsets xml_i="51912" xml_f="51921" txt_i="31736" txt_f="31745">12 (4.4%)</offsets></td><td><offsets xml_i="51930" xml_f="51939" txt_i="31746" txt_f="31755">16 (6.2%)</offsets></td></tr><tr><td><offsets xml_i="51957" xml_f="51978" txt_i="31756" txt_f="31777"> Musculoskeletal pain</offsets></td><td><offsets xml_i="51987" xml_f="51996" txt_i="31778" txt_f="31787">15 (5.6%)</offsets></td><td><offsets xml_i="52005" xml_f="52013" txt_i="31788" txt_f="31796">6 (2.2%)</offsets></td><td><offsets xml_i="52022" xml_f="52030" txt_i="31797" txt_f="31805">5 (1.9%)</offsets></td></tr><tr><td><offsets xml_i="52048" xml_f="52121" txt_i="31806" txt_f="31879">Neoplasms benign, malignant, and unspecified (including cysts and polyps)</offsets></td><td><offsets xml_i="52130" xml_f="52139" txt_i="31880" txt_f="31889">20 (7.5%)</offsets></td><td><offsets xml_i="52148" xml_f="52157" txt_i="31890" txt_f="31899">16 (5.9%)</offsets></td><td><offsets xml_i="52166" xml_f="52175" txt_i="31900" txt_f="31909">21 (8.1%)</offsets></td></tr><tr><td><offsets xml_i="52193" xml_f="52217" txt_i="31910" txt_f="31934">Nervous system disorders</offsets></td><td><offsets xml_i="52226" xml_f="52237" txt_i="31935" txt_f="31946">123 (46.2%)</offsets></td><td><offsets xml_i="52246" xml_f="52257" txt_i="31947" txt_f="31958">126 (46.5%)</offsets></td><td><offsets xml_i="52266" xml_f="52277" txt_i="31959" txt_f="31970">127 (48.8%)</offsets></td></tr><tr><td><offsets xml_i="52295" xml_f="52304" txt_i="31971" txt_f="31980"> Headache</offsets></td><td><offsets xml_i="52313" xml_f="52323" txt_i="31981" txt_f="31991">36 (13.5%)</offsets></td><td><offsets xml_i="52332" xml_f="52342" txt_i="31992" txt_f="32002">34 (12.5%)</offsets></td><td><offsets xml_i="52351" xml_f="52360" txt_i="32003" txt_f="32012">25 (9.6%)</offsets></td></tr><tr><td><offsets xml_i="52378" xml_f="52388" txt_i="32013" txt_f="32023"> Dizziness</offsets></td><td><offsets xml_i="52397" xml_f="52406" txt_i="32024" txt_f="32033">21 (7.9%)</offsets></td><td><offsets xml_i="52415" xml_f="52424" txt_i="32034" txt_f="32043">21 (7.7%)</offsets></td><td><offsets xml_i="52433" xml_f="52443" txt_i="32044" txt_f="32054">27 (10.4%)</offsets></td></tr><tr><td><offsets xml_i="52461" xml_f="52482" txt_i="32055" txt_f="32076">Psychiatric disorders</offsets></td><td><offsets xml_i="52491" xml_f="52501" txt_i="32077" txt_f="32087">76 (28.6%)</offsets></td><td><offsets xml_i="52510" xml_f="52519" txt_i="32088" txt_f="32097">65 (24.0)</offsets></td><td><offsets xml_i="52528" xml_f="52538" txt_i="32098" txt_f="32108">73 (28.1%)</offsets></td></tr><tr><td><offsets xml_i="52556" xml_f="52567" txt_i="32109" txt_f="32120"> Depression</offsets></td><td><offsets xml_i="52576" xml_f="52585" txt_i="32121" txt_f="32130">14 (5.3%)</offsets></td><td><offsets xml_i="52594" xml_f="52603" txt_i="32131" txt_f="32140">23 (8.5%)</offsets></td><td><offsets xml_i="52612" xml_f="52621" txt_i="32141" txt_f="32150">25 (9.6%)</offsets></td></tr><tr><td><offsets xml_i="52639" xml_f="52647" txt_i="32151" txt_f="32159"> Anxiety</offsets></td><td><offsets xml_i="52656" xml_f="52665" txt_i="32160" txt_f="32169">19 (7.1%)</offsets></td><td><offsets xml_i="52674" xml_f="52683" txt_i="32170" txt_f="32179">20 (7.4%)</offsets></td><td><offsets xml_i="52692" xml_f="52701" txt_i="32180" txt_f="32189">16 (6.2%)</offsets></td></tr><tr><td><offsets xml_i="52719" xml_f="52746" txt_i="32190" txt_f="32217">Renal and urinary disorders</offsets></td><td><offsets xml_i="52755" xml_f="52764" txt_i="32218" txt_f="32227">19 (7.1%)</offsets></td><td><offsets xml_i="52773" xml_f="52782" txt_i="32228" txt_f="32237">21 (7.7%)</offsets></td><td><offsets xml_i="52791" xml_f="52800" txt_i="32238" txt_f="32247">22 (8.5%)</offsets></td></tr><tr><td><offsets xml_i="52818" xml_f="52858" txt_i="32248" txt_f="32288">Reproductive system and breast disorders</offsets></td><td><offsets xml_i="52867" xml_f="52876" txt_i="32289" txt_f="32298">12 (4.5%)</offsets></td><td><offsets xml_i="52885" xml_f="52894" txt_i="32299" txt_f="32308">14 (5.2%)</offsets></td><td><offsets xml_i="52903" xml_f="52912" txt_i="32309" txt_f="32318">15 (5.8%)</offsets></td></tr><tr><td><offsets xml_i="52930" xml_f="52978" txt_i="32319" txt_f="32367">Respiratory, thoracic, and mediastinal disorders</offsets></td><td><offsets xml_i="52987" xml_f="52997" txt_i="32368" txt_f="32378">32 (12.0%)</offsets></td><td><offsets xml_i="53006" xml_f="53016" txt_i="32379" txt_f="32389">29 (10.7%)</offsets></td><td><offsets xml_i="53025" xml_f="53035" txt_i="32390" txt_f="32400">33 (12.7%)</offsets></td></tr><tr><td><offsets xml_i="53053" xml_f="53091" txt_i="32401" txt_f="32439">Skin and subcutaneous tissue disorders</offsets></td><td><offsets xml_i="53100" xml_f="53110" txt_i="32440" txt_f="32450">31 (11.7%)</offsets></td><td><offsets xml_i="53119" xml_f="53129" txt_i="32451" txt_f="32461">39 (14.4%)</offsets></td><td><offsets xml_i="53138" xml_f="53148" txt_i="32462" txt_f="32472">39 (15.0%)</offsets></td></tr><tr><td><offsets xml_i="53166" xml_f="53197" txt_i="32473" txt_f="32504">Surgical and medical procedures</offsets></td><td><offsets xml_i="53206" xml_f="53215" txt_i="32505" txt_f="32514">21 (7.9%)</offsets></td><td><offsets xml_i="53224" xml_f="53233" txt_i="32515" txt_f="32524">18 (6.6%)</offsets></td><td><offsets xml_i="53242" xml_f="53251" txt_i="32525" txt_f="32534">18 (6.9%)</offsets></td></tr><tr><td><offsets xml_i="53269" xml_f="53287" txt_i="32535" txt_f="32553">Vascular disorders</offsets></td><td><offsets xml_i="53296" xml_f="53306" txt_i="32554" txt_f="32564">33 (12.4%)</offsets></td><td><offsets xml_i="53315" xml_f="53324" txt_i="32565" txt_f="32574">19 (7.0%)</offsets></td><td><offsets xml_i="53333" xml_f="53343" txt_i="32575" txt_f="32585">30 (11.5%)</offsets></td></tr><tr><td><offsets xml_i="53361" xml_f="53374" txt_i="32586" txt_f="32599"> Hypertension</offsets></td><td><offsets xml_i="53383" xml_f="53392" txt_i="32600" txt_f="32609">18 (6.8%)</offsets></td><td><offsets xml_i="53401" xml_f="53410" txt_i="32610" txt_f="32619">11 (4.1%)</offsets></td><td><offsets xml_i="53419" xml_f="53428" txt_i="32620" txt_f="32629">19 (7.3%)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="53474" xml_f="53546" txt_i="32630" txt_f="32702">Events with an incidence of at least 5% in any treatment group are shown</offsets></p></table-wrap-foot></table-wrap><offsets xml_i="53581" xml_f="53582" txt_i="32703" txt_f="32704">
</offsets><table-wrap id="Tab6"><label><offsets xml_i="53611" xml_f="53618" txt_i="32704" txt_f="32711">Table 6</offsets></label><caption><p><offsets xml_i="53638" xml_f="53686" txt_i="32711" txt_f="32759">Amyloid-related imaging abnormality findings by </offsets><italic><offsets xml_i="53694" xml_f="53698" txt_i="32759" txt_f="32763">APOE</offsets></italic><offsets xml_i="53707" xml_f="53796" txt_i="32763" txt_f="32852"> ε4 genotype and severity of amyloid-related imaging abnormalities-vasogenic edema events</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="53871" xml_f="53878" txt_i="32853" txt_f="32860">Placebo</offsets><break></break><offsets xml_i="53893" xml_f="53894" txt_i="32860" txt_f="32861">(</offsets><italic><offsets xml_i="53902" xml_f="53903" txt_i="32861" txt_f="32862">n</offsets></italic><offsets xml_i="53912" xml_f="53919" txt_i="32862" txt_f="32869"> = 266)</offsets></th><th><offsets xml_i="53928" xml_f="53947" txt_i="32869" txt_f="32888">Gantenerumab 105 mg</offsets><break></break><offsets xml_i="53962" xml_f="53963" txt_i="32888" txt_f="32889">(</offsets><italic><offsets xml_i="53971" xml_f="53972" txt_i="32889" txt_f="32890">n</offsets></italic><offsets xml_i="53981" xml_f="53988" txt_i="32890" txt_f="32897"> = 271)</offsets></th><th><offsets xml_i="53997" xml_f="54016" txt_i="32897" txt_f="32916">Gantenerumab 225 mg</offsets><break></break><offsets xml_i="54031" xml_f="54032" txt_i="32916" txt_f="32917">(</offsets><italic><offsets xml_i="54040" xml_f="54041" txt_i="32917" txt_f="32918">n</offsets></italic><offsets xml_i="54050" xml_f="54057" txt_i="32918" txt_f="32925"> = 260)</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="54090" xml_f="54096" txt_i="32925" txt_f="32931">ARIA-E</offsets></td><td><offsets xml_i="54105" xml_f="54113" txt_i="32932" txt_f="32940">2 (0.8%)</offsets></td><td><offsets xml_i="54122" xml_f="54131" txt_i="32941" txt_f="32950">18 (6.6%)</offsets></td><td><offsets xml_i="54140" xml_f="54150" txt_i="32951" txt_f="32961">35 (13.5%)</offsets><sup><offsets xml_i="54155" xml_f="54156" txt_i="32961" txt_f="32962">a</offsets></sup><offsets xml_i="54162" xml_f="54163" txt_i="32962" txt_f="32963">
</offsets></td></tr><tr><td><offsets xml_i="54181" xml_f="54194" txt_i="32964" txt_f="32977"> 0ε4 patients</offsets></td><td><offsets xml_i="54203" xml_f="54211" txt_i="32978" txt_f="32986">2 (2.5%)</offsets></td><td><offsets xml_i="54220" xml_f="54228" txt_i="32987" txt_f="32995">1 (1.8%)</offsets></td><td><offsets xml_i="54237" xml_f="54247" txt_i="32996" txt_f="33006">11 (11.0%)</offsets></td></tr><tr><td><offsets xml_i="54265" xml_f="54278" txt_i="33007" txt_f="33020"> 1ε4 patients</offsets></td><td><offsets xml_i="54287" xml_f="54288" txt_i="33021" txt_f="33022">0</offsets></td><td><offsets xml_i="54297" xml_f="54305" txt_i="33023" txt_f="33031">6 (5.4%)</offsets></td><td><offsets xml_i="54314" xml_f="54324" txt_i="33032" txt_f="33042">24 (15.0%)</offsets></td></tr><tr><td><offsets xml_i="54342" xml_f="54355" txt_i="33043" txt_f="33056"> 2ε4 patients</offsets></td><td><offsets xml_i="54364" xml_f="54365" txt_i="33057" txt_f="33058">0</offsets></td><td><offsets xml_i="54374" xml_f="54384" txt_i="33059" txt_f="33069">11 (10.7%)</offsets></td><td><offsets xml_i="54393" xml_f="54394" txt_i="33070" txt_f="33071">–</offsets></td></tr><tr><td><offsets xml_i="54412" xml_f="54450" txt_i="33072" txt_f="33110">Maximum severity of ARIA–E, mean (±SD)</offsets><sup><offsets xml_i="54455" xml_f="54456" txt_i="33110" txt_f="33111">b</offsets></sup><offsets xml_i="54462" xml_f="54463" txt_i="33111" txt_f="33112">
</offsets></td><td><offsets xml_i="54472" xml_f="54481" txt_i="33113" txt_f="33122">4.0 (4.2)</offsets></td><td><offsets xml_i="54490" xml_f="54499" txt_i="33123" txt_f="33132">4.0 (2.1)</offsets></td><td><offsets xml_i="54508" xml_f="54517" txt_i="33133" txt_f="33142">5.7 (6.9)</offsets></td></tr><tr><td><offsets xml_i="54535" xml_f="54541" txt_i="33143" txt_f="33149">ARIA-H</offsets></td><td><offsets xml_i="54550" xml_f="54560" txt_i="33150" txt_f="33160">35 (13.2%)</offsets></td><td><offsets xml_i="54569" xml_f="54579" txt_i="33161" txt_f="33171">62 (22.9%)</offsets></td><td><offsets xml_i="54588" xml_f="54598" txt_i="33172" txt_f="33182">42 (16.2%)</offsets><sup><offsets xml_i="54603" xml_f="54604" txt_i="33182" txt_f="33183">a</offsets></sup><offsets xml_i="54610" xml_f="54611" txt_i="33183" txt_f="33184">
</offsets></td></tr><tr><td><offsets xml_i="54629" xml_f="54642" txt_i="33185" txt_f="33198"> 0ε4 patients</offsets></td><td><offsets xml_i="54651" xml_f="54659" txt_i="33199" txt_f="33207">4 (5.1%)</offsets></td><td><offsets xml_i="54668" xml_f="54677" txt_i="33208" txt_f="33217">7 (12.3%)</offsets></td><td><offsets xml_i="54686" xml_f="54696" txt_i="33218" txt_f="33228">11 (11.0%)</offsets></td></tr><tr><td><offsets xml_i="54714" xml_f="54727" txt_i="33229" txt_f="33242"> 1ε4 patients</offsets></td><td><offsets xml_i="54736" xml_f="54746" txt_i="33243" txt_f="33253">19 (14.2%)</offsets></td><td><offsets xml_i="54755" xml_f="54765" txt_i="33254" txt_f="33264">22 (19.8%)</offsets></td><td><offsets xml_i="54774" xml_f="54784" txt_i="33265" txt_f="33275">31 (19.4%)</offsets></td></tr><tr><td><offsets xml_i="54802" xml_f="54815" txt_i="33276" txt_f="33289"> 2ε4 patients</offsets></td><td><offsets xml_i="54824" xml_f="54834" txt_i="33290" txt_f="33300">12 (22.6%)</offsets></td><td><offsets xml_i="54843" xml_f="54853" txt_i="33301" txt_f="33311">33 (32.0%)</offsets></td><td><offsets xml_i="54862" xml_f="54863" txt_i="33312" txt_f="33313">–</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="54909" xml_f="54910" txt_i="33314" txt_f="33315">
</offsets><italic><offsets xml_i="54918" xml_f="54924" txt_i="33315" txt_f="33321">ARIA-E</offsets></italic><offsets xml_i="54933" xml_f="54989" txt_i="33321" txt_f="33377"> Amyloid-related imaging abnormalities-vasogenic edema, </offsets><italic><offsets xml_i="54997" xml_f="55003" txt_i="33377" txt_f="33383">ARIA-H</offsets></italic><offsets xml_i="55012" xml_f="55062" txt_i="33383" txt_f="33433"> Amyloid-related imaging abnormalities-hemosiderin</offsets></p><p><offsets xml_i="55069" xml_f="55070" txt_i="33434" txt_f="33435">
</offsets><sup><offsets xml_i="55075" xml_f="55076" txt_i="33435" txt_f="33436">a</offsets></sup><offsets xml_i="55082" xml_f="55107" txt_i="33436" txt_f="33461">By design, there were no </offsets><italic><offsets xml_i="55115" xml_f="55119" txt_i="33461" txt_f="33465">APOE</offsets></italic><offsets xml_i="55128" xml_f="55172" txt_i="33465" txt_f="33509"> 2ε4 patients in the gantenerumab 225 mg arm</offsets></p><p><offsets xml_i="55179" xml_f="55180" txt_i="33510" txt_f="33511">
</offsets><sup><offsets xml_i="55185" xml_f="55186" txt_i="33511" txt_f="33512">b</offsets></sup><offsets xml_i="55192" xml_f="55214" txt_i="33512" txt_f="33534">ARIA-E rating scale 28</offsets></p></table-wrap-foot></table-wrap><offsets xml_i="55249" xml_f="55250" txt_i="33535" txt_f="33536">
</offsets></p><p id="Par70"><offsets xml_i="55268" xml_f="55368" txt_i="33537" txt_f="33637">Injection site erythema events were all mild to moderate in intensity. ARIA-E events were dose- and </offsets><italic><offsets xml_i="55376" xml_f="55380" txt_i="33637" txt_f="33641">APOE</offsets></italic><offsets xml_i="55389" xml_f="55469" txt_i="33641" txt_f="33721"> ε4 genotype-dependent and occurred rarely in the placebo arm. ARIA-H were also </offsets><italic><offsets xml_i="55477" xml_f="55481" txt_i="33721" txt_f="33725">APOE</offsets></italic><offsets xml_i="55490" xml_f="55566" txt_i="33725" txt_f="33801"> ε4 genotype-dependent and more frequent with gantenerumab treatment (Table </offsets><xref rid="Tab6" ref-type="table"><offsets xml_i="55600" xml_f="55601" txt_i="33801" txt_f="33802">6</offsets></xref><offsets xml_i="55608" xml_f="56020" txt_i="33802" txt_f="34211">). ARIA-E occurred most frequently between 3 and 6 months of treatment; the incidence notably decreased after the first 9 months of treatment, and ARIA-E did not commonly recur (recurrence rate 13.8%) in patients who restarted treatment at half the original dose. The large majority of ARIA-E events (&gt; 80%) were asymptomatic and resolved with dose adjustment. The most commonly reported symptom was headache.</offsets></p></sec></sec><sec id="Sec25"><title><offsets xml_i="56059" xml_f="56069" txt_i="34214" txt_f="34224">Discussion</offsets></title><p id="Par71"><offsets xml_i="56091" xml_f="56848" txt_i="34225" txt_f="34979">In the SCarlet RoAD study, we investigated the effects of 105 mg or 225 mg of SC gantenerumab or placebo given every 4 weeks in patients with prodromal AD. A preplanned futility analysis was conducted on the primary endpoint (CDR-SB change from baseline) when ~ 50% of the patients had completed 2 years of treatment. No differences were observed in primary or secondary efficacy measures across the placebo and treatment arms, and the futility model predicted a &lt; 6% chance of a positive study, which prompted the sponsor to discontinue dosing. These clinical outcomes in prodromal AD are reminiscent of phase III trials in mild to moderate AD with another antiaggregated Aβ antibody, bapineuzumab, in which investigators explored a limited dose range [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="56881" xml_f="56883" txt_i="34979" txt_f="34981">21</offsets></xref><offsets xml_i="56890" xml_f="56892" txt_i="34981" txt_f="34983">, </offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="56925" xml_f="56927" txt_i="34983" txt_f="34985">22</offsets></xref><offsets xml_i="56934" xml_f="57152" txt_i="34985" txt_f="35203">]. Several factors were examined for their contributions to a negative outcome in SCarlet RoAD, including inactive compound, insufficient dosing, short trial duration, insensitive endpoints, and the population studied.</offsets></p><p id="Par72"><offsets xml_i="57170" xml_f="57590" txt_i="35204" txt_f="35624">Despite the lack of a clinical benefit in the overall population, gantenerumab showed evidence of biological activity at the doses tested. Reduction of amyloid load as measured by PET was dose-dependent, indicative of successful target engagement in the brain and a confirmation of gantenerumab’s mechanism of action in a larger dataset and in a population at an earlier stage of the disease than in the earlier report [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="57622" xml_f="57623" txt_i="35624" txt_f="35625">8</offsets></xref><offsets xml_i="57630" xml_f="57914" txt_i="35625" txt_f="35909">]. Furthermore, gantenerumab treatment was associated with a dose-dependent reduction in CSF biomarkers that are thought to reflect core pathological processes of AD, including hyperphosphorylation of tau (p-tau), and downstream processes of neuronal and axonal degeneration (t-tau) [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="57947" xml_f="57949" txt_i="35909" txt_f="35911">23</offsets></xref><offsets xml_i="57956" xml_f="58006" txt_i="35911" txt_f="35961">], as well as synaptic dysfunction (neurogranin) [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="58039" xml_f="58041" txt_i="35961" txt_f="35963">24</offsets></xref><offsets xml_i="58048" xml_f="58050" txt_i="35963" txt_f="35965">].</offsets></p><p id="Par73"><offsets xml_i="58068" xml_f="58445" txt_i="35966" txt_f="36343">Interestingly, in a subgroup of fast progressors, numerical differences in decline between treatment groups as measured by the ADAS-Cog 13 were observed, suggesting a dose-dependent clinical response. Similar dose-dependent trends were observed for MMSE and CANTAB, although not for CDR-SB. In contrast, no such effects were seen in patients predicted to have slow progression.</offsets></p><p id="Par74"><offsets xml_i="58463" xml_f="58638" txt_i="36344" txt_f="36519">In SCarlet RoAD, gantenerumab doses of 105 and 225 mg SC every 4 weeks had been chosen to minimize the risk of ARIA in this mildly affected prodromal AD population. Dose- and </offsets><italic><offsets xml_i="58646" xml_f="58650" txt_i="36519" txt_f="36523">APOE</offsets></italic><offsets xml_i="58659" xml_f="58941" txt_i="36523" txt_f="36805"> ε4 genotype-dependent ARIA were observed, as was injection site erythema. However, most of the ARIA were asymptomatic and rated by the investigators as mild or moderate, and most patients could continue dosing, albeit at a lower (halved) dose, with a low rate of ARIA-E recurrence.</offsets></p><p id="Par75"><offsets xml_i="58959" xml_f="59466" txt_i="36806" txt_f="37313">It is hypothesized that higher doses of gantenerumab that result in more amyloid load reduction may be more likely to result in clinically meaningful efficacy. Recent phase Ib study results with aducanumab, an antibody with a preclinical profile similar to that of gantenerumab which was tested at higher doses in a similar population to the one enrolled in SCarlet RoAD, showed substantially greater and equally dose-dependent amyloid load reduction as measured by PET but also a higher incidence of ARIA [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="59499" xml_f="59501" txt_i="37313" txt_f="37315">25</offsets></xref><offsets xml_i="59508" xml_f="59638" txt_i="37315" txt_f="37445">]. The reported phase Ib results with aducanumab are suggestive of dose-dependent clinical effects; however, the sample was small.</offsets></p><p id="Par76"><offsets xml_i="59656" xml_f="59861" txt_i="37446" txt_f="37651">The apparent dose-dependent clinical effect in fast progressors, combined with the biomarker outcomes in this study with gantenerumab, as well as the positive results of the phase Ib trial for aducanumab [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="59894" xml_f="59896" txt_i="37651" txt_f="37653">25</offsets></xref><offsets xml_i="59903" xml_f="60499" txt_i="37653" txt_f="38249">], suggest that gantenerumab may have been dosed too low to achieve substantial clinical benefit. Achieving higher exposures of gantenerumab while minimizing ARIA rates is expected to be important for a balanced benefit-risk profile. Because ARIA in SCarlet RoAD generally occurred within the first 6 months of dosing, with potentially higher frequency and/or severity at higher doses, it is hypothesized that using titration schemes to achieve high doses may result in substantial brain amyloid reduction that may be clinically beneficial yet minimize both the rate and severity of ARIA events [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="60532" xml_f="60534" txt_i="38249" txt_f="38251">26</offsets></xref><offsets xml_i="60541" xml_f="60983" txt_i="38251" txt_f="38693">]. To test this hypothesis, multiple dose titration regimens are being examined for their ability to minimize ARIA events at higher doses in open-label extensions of the ongoing gantenerumab trials. Whether treatment with an antibody such as gantenerumab at a higher dose provides not only a higher degree of brain amyloid reduction but also a clinical benefit must be demonstrated in randomized, placebo-controlled phase III clinical trials.</offsets></p><p id="Par77"><offsets xml_i="61001" xml_f="61255" txt_i="38694" txt_f="38948">It has been questioned whether it is possible to observe clinically meaningful effects in prodromal AD populations within a 2-year study duration. Although negative phase III trials of anti-Aβ antibodies in mild and moderate AD have been 18 months long [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="61288" xml_f="61290" txt_i="38948" txt_f="38950">21</offsets></xref><offsets xml_i="61297" xml_f="61299" txt_i="38950" txt_f="38952">, </offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="61332" xml_f="61334" txt_i="38952" txt_f="38954">27</offsets></xref><offsets xml_i="61341" xml_f="61531" txt_i="38954" txt_f="39144">], the phase Ib study results with aducanumab mentioned above suggest that clinical effects in an AD population at an earlier stage of the disease can already be identified after 12 months [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="61564" xml_f="61566" txt_i="39144" txt_f="39146">25</offsets></xref><offsets xml_i="61573" xml_f="61689" txt_i="39146" txt_f="39262">]. Therefore, the 2-year study duration in SCarlet RoAD was likely sufficient to show clinically meaningful effects.</offsets></p><p id="Par78"><xref ref-type="bibr" rid="CR28"><offsets xml_i="61740" xml_f="61742" txt_i="39263" txt_f="39265">28</offsets></xref><offsets xml_i="61749" xml_f="61751" txt_i="39265" txt_f="39267">, </offsets><xref ref-type="bibr" rid="CR29"><offsets xml_i="61784" xml_f="61786" txt_i="39267" txt_f="39269">29</offsets></xref><offsets xml_i="61793" xml_f="61813" txt_i="39269" txt_f="39289">] and other groups [</offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="61846" xml_f="61848" txt_i="39289" txt_f="39291">30</offsets></xref><offsets xml_i="61855" xml_f="62001" txt_i="39291" txt_f="39437">]. Recent analysis of the CDR-SB demonstrated test-retest reliability, construct validity to functional change, and sensitivity to decline in AD [</offsets><xref ref-type="bibr" rid="CR31"><offsets xml_i="62034" xml_f="62036" txt_i="39437" txt_f="39439">31</offsets></xref><offsets xml_i="62043" xml_f="62045" txt_i="39439" txt_f="39441">, </offsets><xref ref-type="bibr" rid="CR32"><offsets xml_i="62078" xml_f="62080" txt_i="39441" txt_f="39443">32</offsets></xref><offsets xml_i="62087" xml_f="62579" txt_i="39443" txt_f="39935">]. SCarlet RoAD was the first global phase III study in prodromal AD using amyloid screening. The decline observed in the placebo group was slightly less (1.60 CDR-SB points over 2 years) than expected on the basis of ADNI data (1.92 CDR-SB points over 2 years) available at the time at which the study was designed. However, in another randomized clinical trial in CSF biomarker-supported prodromal AD, the decline in mean CDR-SB points over 2 years (placebo group) was reported to be 1.65 [</offsets><xref ref-type="bibr" rid="CR33"><offsets xml_i="62612" xml_f="62614" txt_i="39935" txt_f="39937">33</offsets></xref><offsets xml_i="62621" xml_f="62734" txt_i="39937" txt_f="40050">]. Hence, the observed decline in CDR-SB is consistent with another recent clinical trial. Other, older reports [</offsets><xref ref-type="bibr" rid="CR34"><offsets xml_i="62767" xml_f="62769" txt_i="40050" txt_f="40052">34</offsets></xref><offsets xml_i="62776" xml_f="63458" txt_i="40052" txt_f="40734">] had suggested a higher placebo decline, but these were observational studies and had other important differences in terms of study design and patient characteristics. The change from baseline in CDR-SB was consistent with changes observed in other measures of cognition (ADAS-Cog 13, MMSE) and function (FAQ). The sensitivity of CDR-SB to drug effects has also been suggested by the aducanumab phase Ib study, as mentioned above. Overall, the choice of CDR-SB as the primary endpoint seemed appropriate for the population examined. The observed rate of decline must be carefully considered in any sample size estimation for future studies if the same population is to be enrolled.</offsets></p><p id="Par79"><offsets xml_i="63476" xml_f="63727" txt_i="40735" txt_f="40986">This report has important limitations. The study was stopped early for futility. All biomarker and clinical signals described resulted from exploratory analyses, some of which were conducted post hoc. Therefore, all analyses presented here, including </offsets><italic><offsets xml_i="63735" xml_f="63736" txt_i="40986" txt_f="40987">p</offsets></italic><offsets xml_i="63745" xml_f="63847" txt_i="40987" txt_f="41089"> values, should be considered as strictly descriptive and hypothesis-generating, but not confirmatory.</offsets></p></sec><sec id="Sec26"><title><offsets xml_i="63880" xml_f="63891" txt_i="41091" txt_f="41102">Conclusions</offsets></title><p id="Par80"><offsets xml_i="63913" xml_f="64760" txt_i="41103" txt_f="41950">In summary, although the SCarlet RoAD study was stopped early for futility, dose-dependent effects observed in exploratory analyses on select clinical and biomarker endpoints suggest that higher dosing with gantenerumab may be necessary to achieve clinical efficacy. Exploratory analyses in a fast progressor subgroup were also suggestive of a dose-dependent effect of gantenerumab on some clinical endpoints. Growing evidence of the manageability of ARIA supports the investigation of higher doses of gantenerumab in subsequent clinical trials. Further phase III clinical trials employing dose titration schemes designed to mitigate the increased rate of ARIA-E expected at higher doses are planned to assess the degree of amyloid reduction by gantenerumab at these doses and to confirm whether such effects are associated with clinical benefits.</offsets></p></sec></body><back><app-group><app id="App1"><sec id="Sec27"><title>Additional file</title><p id="Par87">
<media position="anchor" xlink:href="13195_2017_318_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>List of institutional review boards and independent ethics committees. (DOCX 20 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>Aβ</term><def><p id="Par7">Amyloid-beta</p></def></def-item><def-item><term>AD</term><def><p id="Par8">Alzheimer’s disease</p></def></def-item><def-item><term>ADAS-Cog 13</term><def><p id="Par9">Alzheimer’s Disease Assessment Scale–Cognitive subscale</p></def></def-item><def-item><term>ADNI</term><def><p id="Par10">Alzheimer’s Disease Neuroimaging Initiative</p></def></def-item><def-item><term>APOE</term><def><p id="Par11">Apolipoprotein E</p></def></def-item><def-item><term>ARIA</term><def><p id="Par12">Amyloid-related imaging abnormalities</p></def></def-item><def-item><term>ARIA-E</term><def><p id="Par13">Amyloid-related imaging abnormalities–edema</p></def></def-item><def-item><term>ARIA-H</term><def><p id="Par14">Amyloid-related imaging abnormalities–microbleeds</p></def></def-item><def-item><term>CANTAB</term><def><p id="Par15">Cambridge Neuropsychological Test Automated Battery</p></def></def-item><def-item><term>CDR-SB</term><def><p id="Par16">Clinical Dementia Rating Sum of Boxes</p></def></def-item><def-item><term>AChE</term><def><p id="Par17">Acetylcholinesterase</p></def></def-item><def-item><term>CSF</term><def><p id="Par18">Cerebrospinal fluid</p></def></def-item><def-item><term>FAQ</term><def><p id="Par19">Functional Activities Questionnaire</p></def></def-item><def-item><term>FCSRT</term><def><p id="Par20">Free and Cued Selective Reminding Test</p></def></def-item><def-item><term>GCP</term><def><p id="Par21">Good clinical practice</p></def></def-item><def-item><term>GDS</term><def><p id="Par22">Geriatric Depression Scale</p></def></def-item><def-item><term>IDMC</term><def><p id="Par23">Independent data monitoring committee</p></def></def-item><def-item><term>IV</term><def><p id="Par24">Intravenous</p></def></def-item><def-item><term>MCI</term><def><p id="Par25">Mild cognitive impairment</p></def></def-item><def-item><term>MMRM</term><def><p id="Par26">Mixed-effects model repeated measurement</p></def></def-item><def-item><term>MMSE</term><def><p id="Par27">Mini Mental State Examination</p></def></def-item><def-item><term>MRI</term><def><p id="Par28">Magnetic resonance imaging</p></def></def-item><def-item><term>NPI-Q</term><def><p id="Par29">Neuropsychiatric Inventory Questionnaire</p></def></def-item><def-item><term>PET</term><def><p id="Par30">Positron emission tomography</p></def></def-item><def-item><term>p-tau</term><def><p id="Par31">Phosphorylated tau 181</p></def></def-item><def-item><term>SC</term><def><p id="Par32">Subcutaneous</p></def></def-item><def-item><term>SUVr</term><def><p id="Par33">Standardized uptake value ratio</p></def></def-item><def-item><term>t-tau</term><def><p id="Par34">Total tau</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13195-017-0318-y) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank all the patients with Alzheimer’s disease and their caregivers who participated in this study. We also thank our partners at each of the participating study sites. We thank Estelle Vester-Blokland for her valuable contribution to this project. Editorial support in the form of medical writing was provided by Sam Hurrell of Medologie, part of the Bioscript® group, and was funded by F. Hoffmann-La Roche.</p><sec id="FPar1"><title>Funding</title><p id="Par81">This study was funded by F. Hoffmann-La Roche. FB is supported by the NIHR UCLH biomedical research centre.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par82">The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>SO, ED, TN, and LS designed the study in consultation with BD, KB, FB, and PS. EA, PS, BD, FB, MB, KB, ED, MA, TN, SO, and RAL were involved in data collection and study execution. SR, CH, and PD performed the data analyses and provided guidance regarding the interpretation and presentation of the data. RAL, SO, TN, and PF provided guidance on the data analysis and interpretation and on the presentation of the data. All authors critically reviewed and edited the manuscript, and all authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par83">SCarlet RoAD was approved by individual institution ethics committees or institutional review boards and was conducted in accordance with the principles of the Declaration of Helsinki and good clinical practice (GCP). Please refer to Additional file <xref rid="MOESM1" ref-type="media">1</xref> for details. Written informed consent was obtained from each patient.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par84">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par85">SO, RAL, ED, TN, EA, SR, CH, PD, GK, MA, LS, and PF are current or former employees of F. Hoffmann La-Roche and own stock or stock options in Roche. FB has received consultancy fees/honoraria from Bayer-Schering Pharma, Biogen Idec, Teva, Merck-Serono, Novartis, F. Hoffmann-La Roche, Synthon BV, Janssen Research, and Genzyme. FB has received grants from the Dutch Multiple Sclerosis Society and the European Union Seventh Framework Programme/Horizon 2020 (H2020). FB’s institution has received fees from IXICO for educational presentation development. FB is supported by the National Institute for Health Research-UCL Hospitals Biomedical Research Centre. KB reports receipt of a grant to his institution for performing CSF analyses during the conduct of the study. KB reports receiving personal fees from Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Pfizer, and Roche Diagnostics. KB is the co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. MB reports receiving grants from Elizabeth Forward School District/Lilly Mental Health and Diabetes Program (2014–2015) and from the H2020-JTI-IMI2-2015-05 (EC) (Eli Lilly and AstraZeneca) Models of Patient Engagement for Alzheimer’s Disease (MOPEAD) Project (2016–2018). KB reports receiving personal fees from Grifols, Janssen, Eli Lilly, MSD, Nutricia, Roche, and Servier. PS reports receiving speaker fees from Roche AG during the conduct of the study and consultancy fees from Axovant Sciences, Probiodrug, and EIP Pharma. BD reports receiving personal fees from Eli Lilly and grants from Pfizer.</p></sec><sec id="FPar6"><title>Publisher’s note</title><p id="Par86">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Xiong</surname><given-names>C</given-names></name><name><surname>Benzinger</surname><given-names>TL</given-names></name><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Goate</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><etal></etal></person-group><article-title>Clinical and biomarker changes in dominantly inherited Alzheimer’s disease</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><issue>9</issue><fpage>795</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1202753</pub-id><pub-id pub-id-type="pmid">22784036</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide</article-title><source>Nat Rev Mol Cell Biol</source><year>2007</year><volume>8</volume><issue>2</issue><fpage>101</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/nrm2101</pub-id><pub-id pub-id-type="pmid">17245412</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>de Leon</surname><given-names>MJ</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Alzheimer’s disease</article-title><source>Lancet</source><year>2006</year><volume>368</volume><issue>9533</issue><fpage>387</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69113-7</pub-id><pub-id pub-id-type="pmid">16876668</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Jacova</surname><given-names>C</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Barberger-Gateau</surname><given-names>P</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria</article-title><source>Lancet Neurol</source><year>2007</year><volume>6</volume><issue>8</issue><fpage>734</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(07)70178-3</pub-id><pub-id pub-id-type="pmid">17616482</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>B</given-names></name><name><surname>Lautner</surname><given-names>R</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Ohrfelt</surname><given-names>A</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Bjerke</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis</article-title><source>Lancet Neurol</source><year>2016</year><volume>15</volume><issue>7</issue><fpage>673</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(16)00070-3</pub-id><pub-id pub-id-type="pmid">27068280</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bard</surname><given-names>F</given-names></name><name><surname>Cannon</surname><given-names>C</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Burke</surname><given-names>RL</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Grajeda</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><issue>8</issue><fpage>916</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/78682</pub-id><pub-id pub-id-type="pmid">10932230</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrowitzki</surname><given-names>S</given-names></name><name><surname>Deptula</surname><given-names>D</given-names></name><name><surname>Thurfjell</surname><given-names>L</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Bohrmann</surname><given-names>B</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><issue>2</issue><fpage>198</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.1538</pub-id><pub-id pub-id-type="pmid">21987394</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>WG</given-names></name><name><surname>Terry</surname><given-names>RD</given-names></name><name><surname>Fuld</surname><given-names>PA</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Peck</surname><given-names>A</given-names></name></person-group><article-title>Pathological verification of ischemic score in differentiation of dementias</article-title><source>Ann Neurol</source><year>1980</year><volume>7</volume><issue>5</issue><fpage>486</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/ana.410070516</pub-id><pub-id pub-id-type="pmid">7396427</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>JC</given-names></name></person-group><article-title>The Clinical Dementia Rating (CDR): current version and scoring rules</article-title><source>Neurology</source><year>1993</year><volume>43</volume><issue>11</issue><fpage>2412</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1212/WNL.43.11.2412-a</pub-id><pub-id pub-id-type="pmid">8232972</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleisher</surname><given-names>AS</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Roontiva</surname><given-names>A</given-names></name><name><surname>Thiyyagura</surname><given-names>P</given-names></name><name><surname>Ayutyanont</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease</article-title><source>Arch Neurol</source><year>2011</year><volume>68</volume><issue>11</issue><fpage>1404</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.150</pub-id><pub-id pub-id-type="pmid">21747008</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>CC</given-names></name><name><surname>Ackerman</surname><given-names>U</given-names></name><name><surname>Browne</surname><given-names>W</given-names></name><name><surname>Mulligan</surname><given-names>R</given-names></name><name><surname>Pike</surname><given-names>KL</given-names></name><name><surname>O’Keefe</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Imaging of amyloid beta in Alzheimer’s disease with 18 F-BAY94-9172, a novel PET tracer: proof of mechanism</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><issue>2</issue><fpage>129</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(08)70001-2</pub-id><pub-id pub-id-type="pmid">18191617</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeborough</surname><given-names>PA</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name></person-group><article-title>The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI</article-title><source>IEEE Trans Med Imaging</source><year>1997</year><volume>16</volume><issue>5</issue><fpage>623</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1109/42.640753</pub-id><pub-id pub-id-type="pmid">9368118</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>KK</given-names></name><name><surname>Clarkson</surname><given-names>MJ</given-names></name><name><surname>Bartlett</surname><given-names>JW</given-names></name><name><surname>Clegg</surname><given-names>S</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Weiner</surname><given-names>MW</given-names></name><etal></etal></person-group><article-title>Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection</article-title><source>Neuroimage</source><year>2010</year><volume>50</volume><issue>2</issue><fpage>516</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.12.059</pub-id><pub-id pub-id-type="pmid">20034579</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bittner</surname><given-names>T</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Ostlund</surname><given-names>RE</given-names><suffix>Jr</suffix></name><name><surname>Militello</surname><given-names>M</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><etal></etal></person-group><article-title>Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid</article-title><source>Alzheimers Dement</source><year>2016</year><volume>12</volume><issue>5</issue><fpage>517</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2015.09.009</pub-id><pub-id pub-id-type="pmid">26555316</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Neurochemical dissection of synaptic pathology in Alzheimer’s disease</article-title><source>Int Psychogeriatr</source><year>1998</year><volume>10</volume><issue>1</issue><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1017/S1041610298005110</pub-id><pub-id pub-id-type="pmid">9629521</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Neurogranin levels in cerebrospinal fluid: a new addition to the Alzheimer disease diagnostic toolbox</article-title><source>JAMA Neurol</source><year>2015</year><volume>72</volume><issue>11</issue><fpage>1237</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2015.2075</pub-id><pub-id pub-id-type="pmid">26368650</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kvartsberg</surname><given-names>H</given-names></name><name><surname>Duits</surname><given-names>FH</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Ohrfelt</surname><given-names>A</given-names></name><name><surname>Andersson</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease</article-title><source>Alzheimers Dement</source><year>2015</year><volume>11</volume><issue>10</issue><fpage>1180</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.10.009</pub-id><pub-id pub-id-type="pmid">25533203</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Daams</surname><given-names>M</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Brashear</surname><given-names>HR</given-names></name><name><surname>Arrighi</surname><given-names>HM</given-names></name><name><surname>Bechten</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion</article-title><source>AJNR Am J Neuroradiol</source><year>2013</year><volume>34</volume><issue>8</issue><fpage>1550</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A3475</pub-id><pub-id pub-id-type="pmid">23436056</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delor</surname><given-names>I</given-names></name><name><surname>Charoin</surname><given-names>JE</given-names></name><name><surname>Gieschke</surname><given-names>R</given-names></name><name><surname>Retout</surname><given-names>S</given-names></name><name><surname>Jacqmin</surname><given-names>P</given-names></name></person-group><article-title>Modeling Alzheimer’s disease progression using disease onset time and disease trajectory concepts applied to CDR-SOB scores from ADNI</article-title><source>CPT Pharmacometrics Syst Pharmacol.</source><year>2013</year><volume>2</volume><fpage>e78</fpage><pub-id pub-id-type="doi">10.1038/psp.2013.54</pub-id><pub-id pub-id-type="pmid">24088949</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Klunk</surname><given-names>W</given-names></name><name><surname>Raskind</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>4</issue><fpage>322</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1304839</pub-id><pub-id pub-id-type="pmid">24450891</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenberghe</surname><given-names>R</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Boada</surname><given-names>M</given-names></name><name><surname>Katayama</surname><given-names>S</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials</article-title><source>Alzheimers Res Ther</source><year>2016</year><volume>8</volume><issue>1</issue><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s13195-016-0189-7</pub-id><pub-id pub-id-type="pmid">27176461</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Cerebrospinal fluid and plasma biomarkers in Alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2010</year><volume>6</volume><issue>3</issue><fpage>131</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2010.4</pub-id><pub-id pub-id-type="pmid">20157306</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kester</surname><given-names>MI</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Crimmins</surname><given-names>DL</given-names></name><name><surname>Herries</surname><given-names>EM</given-names></name><name><surname>Ladenson</surname><given-names>JH</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease</article-title><source>JAMA Neurol</source><year>2015</year><volume>72</volume><issue>11</issue><fpage>1275</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2015.1867</pub-id><pub-id pub-id-type="pmid">26366630</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevigny</surname><given-names>J</given-names></name><name><surname>Chiao</surname><given-names>P</given-names></name><name><surname>Bussiere</surname><given-names>T</given-names></name><name><surname>Weinreb</surname><given-names>PH</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><name><surname>Maier</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease</article-title><source>Nature</source><year>2016</year><volume>537</volume><issue>7618</issue><fpage>50</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature19323</pub-id><pub-id pub-id-type="pmid">27582220</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viglietta</surname><given-names>V</given-names></name><name><surname>O’Gorman</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Sandrock</surname><given-names>A</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Randomized, double-blind, placebo-controlled studies to evaluate treatment with aducanumab (BIIB037) in patients with early Alzheimer’s disease: phase 3 study design [abstract]</article-title><source>Neurology</source><year>2016</year><volume>86</volume><issue>16 Suppl</issue><fpage>S1.003</fpage><pub-id pub-id-type="pmid">27500293</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doody</surname><given-names>RS</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><collab>Alzheimer’s Disease Cooperative Study Data Analysis and Publication Committee</collab></person-group><article-title>Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>15</issue><fpage>1460</fpage><pub-id pub-id-type="pmid">24716687</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">European Medicines Agency (EMA). Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias. London: EMA; 23 Oct 2014. <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176827.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176827.pdf</ext-link>. Accessed 7 July 2017.</mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Food and Drug Administration (FDA). Guidance for industry. Alzheimer’s disease: developing drugs for the treatment of early stage disease Silver Spring, MD: Center for Drug Evaluation and Research, FDA; Feb 2013. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338287.pdf">https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338287.pdf</ext-link>. Accessed 7 July 2017.</mixed-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cedarbaum</surname><given-names>JM</given-names></name><name><surname>Jaros</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>C</given-names></name><name><surname>Coley</surname><given-names>N</given-names></name><name><surname>Andrieu</surname><given-names>S</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><issue>1 Suppl</issue><fpage>S45</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.11.002</pub-id><pub-id pub-id-type="pmid">22658286</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coley</surname><given-names>N</given-names></name><name><surname>Andrieu</surname><given-names>S</given-names></name><name><surname>Jaros</surname><given-names>M</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><name><surname>Cedarbaum</surname><given-names>J</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name></person-group><article-title>Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><issue>6</issue><fpage>602</fpage><lpage>10.e2</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.01.005</pub-id><pub-id pub-id-type="pmid">21745761</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Edgar C, Rylands A, Volz D, Mertes M, Gruendl E, Fontoura P, Santarelli L, Lasser R. Comparative traditional psychometrics of cognitive and functional endpoints in a prodromal Alzheimer’s disease population. Presented at Clinical Trials on Alzheimer’s Disease conference, Barcelona, Spain, November 2015</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coric</surname><given-names>V</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Brody</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial</article-title><source>JAMA Neurol</source><year>2015</year><volume>72</volume><issue>11</issue><fpage>1324</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2015.0607</pub-id><pub-id pub-id-type="pmid">26414022</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>MM</given-names></name><name><surname>Storandt</surname><given-names>M</given-names></name><name><surname>Roe</surname><given-names>CM</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name></person-group><article-title>Progression of Alzheimer disease as measured by Clinical Dementia Rating Sum of Boxes scores</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><issue>1 Suppl</issue><fpage>S39</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2012.01.005</pub-id><pub-id pub-id-type="pmid">22858530</pub-id></element-citation></ref></ref-list></back></article>